Member Publications

Members of the NASH Roundtable™ contribute important research to the public domain through peer-reviewed articles in medical journals. Below is a selection of recent research co-authored by Roundtable members. For a comprehensive search of NASH-related research by Roundtable members and others, visit pubmed.gov.

Filter


The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States

Geier A, Heinz S, Balp MM, Brass C, Pedrosa M, Cai J, Hoad R, Sayadian AC, Rinella M, Ratziu V. J Gastrointestin Liver Dis. 2022 Sep 15;31(3):317-322. doi: 10.15403/jgld-4275.

View Publication

Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease

Huang DQ, Sharpton SR, Amangurbanova M, Tamaki N, Sirlin CB, Loomba R; NAFLD Research Study Group. Clin Gastroenterol Hepatol. 2022 Sep 5:S1542-3565(22)00832-1. doi: 10.1016/j.cgh.2022.08.036.

View Publication

Geographical similarity and differences in the burden and genetic predisposition of NAFLD

Yip TC, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL, Adams LA, de Lédinghen V, Sookoian S, Wong VW. Hepatology. 2022 Sep 5. doi: 10.1002/hep.32774.

View Publication

Non-alcoholic steatohepatitis

Romero-Gómez M. Med Clin (Barc). 2022 Sep 5:S0025-7753(22)00403-1. doi: 10.1016/j.medcli.2022.06.017.

View Publication

Interactive Role of Surrogate Liver Fibrosis Assessment and Insulin Resistance on the Incidence of Major Cardiovascular Events

Martinez-Urbistondo D, D'Avola D, Navarro-González D, Sanchez-Iñigo L, Fernandez-Montero A, Perez-Diaz-Del-Campo N, Bugianesi E, Martinez JA, Pastrana JC. J Clin Med. 2022 Sep 1;11(17):5190. doi: 10.3390/jcm11175190.

View Publication

Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease

Chhatwal J, Dalgic OO, Chen W, Samur S, Bethea ED, Xiao J, Hur C, Corey KE, Loomba R. JAMA Netw Open. 2022 Sep 1;5(9):e2230426. doi: 10.1001/jamanetworkopen.2022.30426.

View Publication

Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine

Perez-Diaz-Del-Campo N, Martínez-Urbistondo D, Bugianesi E, Martínez JA. Curr Opin Clin Nutr Metab Care. 2022 Sep 1;25(5):285-291. doi: 10.1097/MCO.0000000000000849. Epub 2022 Jul 5.

View Publication

Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world

Henry L, Paik J, Younossi ZM. Aliment Pharmacol Ther. 2022 Sep;56(6):942-956. doi: 10.1111/apt.17158. Epub 2022 Jul 26.

View Publication

Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH

Tan DJH, Setiawan VW, Ng CH, Lim WH, Muthiah MD, Tan EX, Dan YY, Roberts LR, Loomba R, Huang DQ. Hepatology. 2022 Aug 29. doi: 10.1002/hep.32758.

View Publication

Shared mechanisms between cardiovascular disease and NAFLD

Huang D, Downes M, Evans R, Witztum J, Glass C, Loomba R. Semin Liver Dis. 2022 Aug 25. doi: 10.1055/a-1930-6658.

View Publication

Management of NAFLD in primary care settings

Wong VWS, Zelber-Sagi S, Cusi K, Carrieri P, Wright E, Crespo J, Lazarus JV. Liver Int. 2022 Aug 20. doi: 10.1111/liv.15404

View Publication

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease

Sen P, Govaere O, Sinioja T, McGlinchey A, Geng D, Ratziu V, Bugianesi E, Schattenberg JM, Vidal-Puig A, Allison M, Cockell S, Daly AK, Hyötyläinen T, Anstee QM, Orešič M. iScience. 2022 Aug 15;25(9):104949. doi: 10.1016/j.isci.2022.104949.

View Publication

Metabolic factors predict changes in endothelial function during the early course of type 1 and type 2 diabetes

Zaharia OP, Schön M, Löffler L, Strassburger K, Möser C, Yurchenko I, Bódis K, Antoniou S, Karusheva Y, Szendroedi J, Burkart V, Roden M. J Clin Endocrinol Metab. 2022 Aug 15:dgac480. doi: 10.1210/clinem/dgac480.

View Publication

Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD

Kim BK, Tamaki N, Imajo K, Yoneda M, Sutter N, Jung J, Lin T, Tu XM, Bergstrom J, Nguyen K, Nguyen L, Le T, Madamba E, Richards L, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. J Hepatol. 2022 Aug 13:S0168-8278(22)02984-1. doi: 10.1016/j.jhep.2022.07.020.

View Publication

Historical Changes in Weight Classes and the Influence of NAFLD Prevalence: A Population Analysis of 34,486 Individuals

Nah BKY, Ng CH, Chan KE, Tan C, Aggarwal M, Zeng RW, Xiao J, Chin YH, Tan EXX, Ren YP, Chee D, Neo J, Chew NWS, Tseng M, Siddiqui MS, Sanyal AJ, Dan YY, Muthiah M. Int J Environ Res Public Health. 2022 Aug 11;19(16):9935. doi: 10.3390/ijerph19169935.

View Publication

Developing and pilot testing an oral health screening tool for diabetes care providers

George A, Poudel P, Kong A, Villarosa A, Calache H, Arora A, Griffiths R, Wong VW, Gussy M, Martin RE, Lau P. BMC Prim Care. 2022 Aug 11;23(1):202. doi: 10.1186/s12875-022-01798-5.

View Publication

Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality

Ng CH, Wong ZY, Chew NWS, Chan KE, Xiao J, Sayed N, Lim WH, Tan DJH, Loke RWK, Tay PWL, Yong JN, Kong G, Huang DQ, Wang JW, Chan M, Dalakoti M, Tamaki N, Noureddin M, Siddiqui MS, Sanyal AJ, Muthiah M. Front Cardiovasc Med. 2022 Aug 8;9:942753. doi: 10.3389/fcvm.2022.942753.

View Publication

Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients’ perspectives

Ng CH, Lim WH, Chin YH, Yong JN, Zeng RW, Chan KE, Tan DJH, Fu CE, Tang ASP, Goh LH, Devi K, Chew NWS, Mak LL, Tamaki N, Huang DQ, Noureddin M, Siddiqui MS, Loomba R, Sanyal AJ, Muthiah M. Aliment Pharmacol Ther. 2022 Aug;56(4):570-579. doi: 10.1111/apt.17121.

View Publication

The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database

Alkhouri N, Almomani A, Le P, Payne JY, Asaad I, Sakkal C, Vos M, Noureddin M, Kumar P. BMC Gastroenterol. 2022 Jul 30;22(1):366. doi: 10.1186/s12876-022-02430-7.

View Publication

Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals

Saponaro C, Sabatini S, Gaggini M, Carli F, Rosso C, Positano V, Armandi A, Caviglia GP, Faletti R, Bugianesi E, Gastaldelli A. Liver Int. 2022 Jul 28. doi: 10.1111/liv.15377.

View Publication

Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health

Sharma A, Albhaisi S, Sanyal AJ. Clin Liver Dis (Hoboken). 2022 Jul 16;20(2):48-51. doi: 10.1002/cld.1219.

View Publication

Behavioral health disorders related to nonalcoholic steatohepatitis

Sharma A, Albhaisi S, Sanyal AJ. Clin Liver Dis (Hoboken). 2022 Jul 16;20(2):43-47. doi: 10.1002/cld.1211.

View Publication

Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients

Lawitz EJ, Li KW, Nyangau E, Field TJ, Chuang JC, Billin A, Wang L, Wang Y, Huss RS, Chung C, Subramanian GM, Myers RP, Hellerstein MK. J Lipid Res. 2022 Jul 11;63(9):100250. doi: 10.1016/j.jlr.2022.100250.

View Publication

Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey

Rinella M, Cryer DR, Articolo A, Fisher T, Schneider J, Nadolsky K. BMC Gastroenterol. 2022 Jul 10;22(1):335. doi: 10.1186/s12876-022-02410-x.

View Publication

The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting

Thrift AP, Nguyen TH, Pham C, Balakrishnan M, Kanwal F, Loomba R, Duong HT, Ramsey D, El-Serag HB. Clin Gastroenterol Hepatol. 2022 Jul 8:S1542-3565(22)00603-6. doi: 10.1016/j.cgh.2022.05.046.

View Publication

Liver stiffness accuracy by MR elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort

Lara Romero C, Liang JX, Fernández Lizaranzazu I, Ampuero Herrojo J, Castell J, Del Prado Alba C, Domínguez Pascual I, Romero Gómez M. Rev Esp Enferm Dig. 2022 Jul 6. doi: 10.17235/reed.2022.8777/2022.

View Publication

Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease

Lin H, Yip TC, Zhang X, Li G, Tse YK, Hui VW, Liang LY, Lai JC, Chan SL, Chan HL, Wong GL, Wong VW. Hepatology. 2022 Jul 5. doi: 10.1002/hep.32633

View Publication

Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer

Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003.

View Publication

The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis

Pistorio V, Tokgozoglu J, Ratziu V, Gautheron J. J Mol Med (Berl). 2022 Jul;100(7):1039-1042. doi: 10.1007/s00109-022-02217-z.

View Publication

Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants

Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Quach NE, Tu X, Zhang X, Noureddin M, Allen AM, Loomba R. Gastroenterology. 2022 Jul 2:S0016-5085(22)00735-1. doi: 10.1053/j.gastro.2022.06.073.

View Publication

Fatty liver indices and their association with glucose metabolism in pregnancy – An observational cohort study.

Linder T, Eppel D, Kotzaeridi G, Rosicky I, Yerlikaya-Schatten G, Kiss H, Weißhaupt K, Henrich W, Bozkurt L, Tura A, Roden M, Göbl CS. Diabetes Res Clin Pract. 2022 Jul;189:109942. doi: 10.1016/j.diabres.2022.109942.

View Publication

A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer

Walford GA, Duncan KE, Hernandez M, Vaddady P, Hompesch M, Morrow L, Stoch SA. Clin Pharmacol Ther. 2022 Jul;112(1):125-132. doi: 10.1002/cpt.2607.

View Publication

Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH

Naoumov NV, Brees D, Loeffler J, Chng E, Ren Y, Lopez P, Tai D, Lamle S, Sanyal AJ. J Hepatol. 2022 Jun 30:S0168-8278(22)00412-3. doi: 10.1016/j.jhep.2022.06.018.

View Publication

Current therapies and new developments in NASH

Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S. Gut. 2022 Jun 16:gutjnl-2021-326874. doi: 10.1136/gutjnl-2021-326874.

View Publication

Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores

Wu Y, Yang X, Morris HL, Gurka MJ, Shenkman EA, Cusi K, Bril F, Donahoo WT. JMIR Med Inform. 2022 Jun 6;10(6):e36997. doi: 10.2196/36997.

View Publication

Breakthroughs in therapies for NASH and remaining challenges

Ratziu V, Francque S, Sanyal A. J Hepatol. 2022 Jun;76(6):1263-1278. doi: 10.1016/j.jhep.2022.04.002.

View Publication

A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

Vujkovic M, Ramdas S, Lorenz KM, Guo X, Darlay R, Cordell HJ, He J, Gindin Y, Chung C, Myers RP, Schneider CV, Park J, Lee KM, Serper M, Carr RM, Kaplan DE, Haas ME, MacLean MT, Witschey WR, Zhu X, Tcheandjieu C, Kember RL, Kranzler HR, Verma A, Giri A, Klarin DM, Sun YV, Huang J, Huffman JE, Townsend Creasy K, Hand NJ, Liu CT, Long MT, Yao J, Budoff M, Tan J, Li X, Lin HJ, Chen YI, Taylor KD, Chang RK, Krauss RM, Vilarinho S, Brancale J, Nielsen JB, Locke AE, Jones MB, Verweij N, Baras A, Reddy KR, Neuschwander-Tetri BA, Schwimmer JB, Sanyal AJ, Chalasani N, Ryan KA, Mitchell BD, Gill D, Wells AD, Manduchi E, Saiman Y, Mahmud N, Miller DR, Reaven PD, Phillips LS, Muralidhar S, DuVall SL, Lee JS, Assimes TL, Pyarajan S, Cho K, Edwards TL, Damrauer SM, Wilson PW, Gaziano JM, O'Donnell CJ, Khera AV, Grant SFA, Brown CD, Tsao PS, Saleheen D, Lotta LA, Bastarache L, Anstee QM, Daly AK, Meigs JB, Rotter JI, Lynch JA; Regeneron Genetics Center; Geisinger-Regeneron DiscovEHR Collaboration; EPoS Consortium; VA Million Veteran Program, Rader DJ, Voight BF, Chang KM. Nat Genet. 2022 Jun 2. doi: 10.1038/s41588-022-01078-z.

View Publication

Clinical features and outcomes of NAFLD-related hepatocellular carcinoma – Authors’ reply

Tan DJH, Ng CH, Muthiah MD, Loomba R, Huang DQ. Lancet Oncol. 2022 Jun;23(6):e244. doi: 10.1016/S1470-2045(22)00265-0.

View Publication

African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population

Cavalcante LN, Porto J, Mazo D, Longatto-Filho A, Stefano JT, Lyra AC, Carrilho FJ, Reis RM, Alves VAF, Sanyal AJ, Oliveira CP. Ann Hepatol. 2022 Jun 13:100728. doi: 10.1016/j.aohep.2022.100728.

View Publication

Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease

Newton KP, Wilson LA, Crimmins NA, Fishbein MH, Molleston JP, Xanthakos SA, Behling C, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network. Clin Gastroenterol Hepatol. 2022 Jun 13:S1542-3565(22)00556-0. doi: 10.1016/j.cgh.2022.05.028.

View Publication

Artificial Intelligence Improves Pathologist Agreement for Fibrosis Scores in Nonalcoholic Steatohepatitis Patients

Soon GST, Liu F, Leow WQ, Wee A, Wei L, Sanyal AJ. Clin Gastroenterol Hepatol. 2022 Jun 10:S1542-3565(22)00555-9. doi: 10.1016/j.cgh.2022.05.027.

View Publication

Hepatic Stellate Cell-Immune Interactions in NASH

Carter JK, Friedman SL. Front Endocrinol (Lausanne). 2022 Jun 9;13:867940. doi: 10.3389/fendo.2022.867940.

View Publication

Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts

Zaharia OP, Lanzinger S, Rosenbauer J, Karges W, Müssig K, Meyhöfer SM, Burkart V, Hummel M, Raddatz D, Roden M, Szendroedi J, Holl RW. Front Endocrinol (Lausanne). 2022 Jun 3;13:760778. doi: 10.3389/fendo.2022.760778.

View Publication

Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool

Marañón P, Fernández-García CE, Isaza SC, Rey E, Gallego-Durán R, Montero-Vallejo R, de Cía JR, Ampuero J, Romero-Gómez M, García-Monzón C, González-Rodríguez Á. Biomark Res. 2022 May 25;10(1):35. doi: 10.1186/s40364-022-00383-3.

View Publication

The Effect of Diabetes and Prediabetes on the Prevalence, Complications and Mortality in Non-alcoholic Fatty Liver Disease

Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH, Tan DJH, Khoo CM, Goh LH, Ling ZJ, Kulkarni A, Mak LL, Huang DQ, Chan M, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M. Clin Mol Hepatol. 2022 May 19. doi: 10.3350/cmh.2022.0096.

View Publication

Prevalence estimation of significant fibrosis due to NASH in Spain combining transient elastography and histology

Calleja JL, Rivera-Esteban J, Aller R, Hernández Conde M, Abad J, Pericàs JM, Gonzalo Benito H, Serra MÁ, Escudero A, Ampuero J, Lucena A, Sánchez Y, Arias-Loste MT, Iruzubieta P, Romero-Gómez M, Augustin S, Crespo J. Liver Int. 2022 May 28. doi: 10.1111/liv.15323.

View Publication

Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis

Sharpton SR, Podlaha O, Chuang JC, Gindin Y, Myers RP, Loomba R. Therap Adv Gastroenterol. 2022 May 18;15:17562848221098243. doi: 10.1177/17562848221098243.

View Publication

Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study

Vali Y, Eijk R, Hicks T, Jones WS, Suklan J, Holleboom AG, Ratziu V, Langendam MW, Anstee QM, Bossuyt PMM; LITMUS Investigators. J Clin Med. 2022 May 11;11(10):2707. doi: 10.3390/jcm11102707.

View Publication

Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD

Smirnova E, Muthiah MD, Narayan N, Siddiqui MS, Puri P, Luketic VA, Contos MJ, Idowu M, Chuang JC, Billin AN, Huss RS, Myers RP, Boyett S, Seneshaw M, Min HK, Mirshahi F, Sanyal AJ. Hepatology. 2022 May 13. doi: 10.1002/hep.32568.

View Publication

Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018

Truong E, Yeo YH, Cook-Wiens G, Muthiah M, Yang JD, Sundaram V, Chang D, Todo T, Kim IK, Lu SC, Setiawan VW, Wong VWS, Harrison SA, Alkhouri N, Noureddin M. Hepatol Commun. 2022 May 9. doi: 10.1002/hep4.1981.

View Publication

Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease

Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Curr Atheroscler Rep. 2022 May 4. doi: 10.1007/s11883-022-01027-5.

View Publication

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis

Sinakos E, Liava C, Loomba R. Ann Gastroenterol. 2022 May-Jun;35(3):213-225. doi: 10.20524/aog.2022.0704.

View Publication

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

View Publication

NAFLD/NASH

Bugianesi E, Petta S. J Hepatol. 2022 May 2:S0168-8278(22)00081-2. doi: 10.1016/j.jhep.2022.02.006.

View Publication

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

View Publication

Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis

Ng CH, Lim WH, Hui Lim GE, Hao Tan DJ, Syn N, Muthiah MD, Huang DQ, Loomba R. Clin Gastroenterol Hepatol. 2022 May 2:S1542-3565(22)00439-6. doi: 10.1016/j.cgh.2022.04.014.

View Publication

Response to: “Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?”

Barb D, Cusi K. Obesity (Silver Spring). 2022 May;30(5):971-972. doi: 10.1002/oby.23422.

View Publication

Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH

Vilalta A, Gutiérrez JA, Chaves S, Hernández M, Urbina S, Hompesch M. Endocrinol Diabetes Metab. 2022 May;5(3):e00335. doi: 10.1002/edm2.335.

View Publication

A global view of the interplay between non-alcoholic fatty liver disease and diabetes.

Stefan N, Cusi K. Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296. doi: 10.1016/S2213-8587(22)00003-1.

View Publication

Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes.

Gancheva S, Kahl S, Pesta D, Mastrototaro L, Dewidar B, Strassburger K, Sabah E, Esposito I, Weiß J, Sarabhai T, Wolkersdorfer M, Fleming T, Nawroth P, Zimmermann M, Reichert AS, Schlensak M, Roden M. Diabetes Care. 2022 Apr 1;45(4):928-937. doi: 10.2337/dc21-1758.

View Publication

Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.

Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez SJ, Gupta H, Sirlin CB, Marks RM, Loomba R. Aliment Pharmacol Ther. 2022 Apr;55(7):820-827. doi: 10.1111/apt.16844.

View Publication

A nutrigenetic tool for precision dietary management of NAFLD deeming insulin resistance markers

Perez-Diaz-Del-Campo N, Riezu-Boj JI, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Milagro FI, Bugianesi E, Tur JA, Martinez JA, Abete I, Zulet MA. Panminerva Med. 2022 Apr 19. doi: 10.23736/S0031-0808.22.04590-6.

View Publication

Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science

Fouad Y, Palmer M, Chen M, Regev A, Banerjee R, Myers R, Riccio R, Torstenson R, Younes R, Arora PS, Landgren H, Karsdal MA, Blake M, Shapiro DA, Gruss HJ, Sheikh MY, Attia D, Bollipo S, Smith AD, Freilich B, Gish RG, Schuppan D. J Clin Transl Hepatol. 2022 Apr 28;10(2):374-382. doi: 10.14218/JCTH.2021.00408.

View Publication

Greater ectopic fat deposition and liver fibroinflammation, and lower skeletal muscle mass in people with type 2 diabetes

Waddell T, Bagur A, Cunha D, Thomaides-Brears H, Banerjee R, Cuthbertson DJ, Brown E, Cusi K, Després JP, Brady M. Obesity (Silver Spring). 2022 Apr 27. doi: 10.1002/oby.23425.

View Publication

Risk of liver-related events by age and diabetes duration in diabetic patients with non-alcoholic fatty liver disease.

Zhang X, Wong GL, Yip TC, Cheung JTK, Tse YK, Hui VW, Lin H, Lai JC, Chan HL, Kong AP, Wong VW. Hepatology. 2022 Mar 25. doi: 10.1002/hep.32476.

View Publication

Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.

Jung J, Han A, Madamba E, Bettencourt R, Loomba RR, Boehringer AS, Andre MP, Erdman JW Jr, O'Brien WD Jr, Fowler KJ, Sirlin CB, Loomba R. Radiology. 2022 Mar 29:211131. doi: 10.1148/radiol.211131.

View Publication

Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.

Tamaki N, Kurosaki M, Huang DQ, Loomba R. Hepatol Res. 2022 Mar 30. doi: 10.1111/hepr.13764.

View Publication

Non-Alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet.

Cusi K. J Clin Endocrinol Metab. 2022 Mar 25:dgac186. doi: 10.1210/clinem/dgac186.

View Publication

A Simple Test to Identify the Risk of NASH and Cirrhosis in People with Obesity or Diabetes: The Time to Screen is Now.

Cusi K. J Clin Endocrinol Metab. 2022 Mar 25:dgac186. doi: 10.1210/clinem/dgac186.

View Publication

Reliability of Histologic Assessment for NAFLD and Development of an Expanded NAFLD Activity Score.

Pai RK, Jairath V, Hogan M, Zou G, Adeyi OA, Anstee QM, Aqel BA, Behling C, Carey EJ, Clouston AD, Corey K, Feagan BG, Kleiner DE, Ma C, McFarlane SC, Noureddin M, Ratziu V, Valasek MA, Younossi ZM, Harrison SA, Loomba R. Hepatology. 2022 Mar 25. doi: 10.1002/hep.32475.

View Publication

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.

Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, Bashir MR, Freilich B, Kohli A, Khazanchi A, Sheikh MY, Leibowitz M, Rinella ME, Siddiqui MS, Kipnes M, Moussa SE, Younes ZH, Bansal M, Baum SJ, Borg B, Ruane PJ, Thuluvath PJ, Gottwald M, Khan M, Chen C, Melchor-Khan L, Chang W, DePaoli AM, Ling L, Lieu HD. Lancet Gastroenterol Hepatol. 2022 Mar 21:S2468-1253(22)00017-6. doi: 10.1016/S2468-1253(22)00017-6.

View Publication

Is lean non-alcoholic fatty liver disease a distinct entity?

Lin H, Wong VW. Hepatol Int. 2022 Mar 24. doi: 10.1007/s12072-022-10324-9.

View Publication

Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.

Ampuero J, Gallego-Durán R, Maya-Miles D, Montero R, Gato S, Rojas Á, Gil A, Muñoz R, Romero-Gómez M. J Gastroenterol. 2022 Mar 24. doi: 10.1007/s00535-022-01860-0.

View Publication

Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.

Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Tan DJH, Yong JN, Pan XH, Koh JWH, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Aliment Pharmacol Ther. 2022 Mar 14. doi: 10.1111/apt.16808.

View Publication

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

Deckmyn O, Poynard T, Bedossa P, Paradis V, Peta V, Pais R, Ratziu V, Thabut D, Brzustowski A, Gautier JF, Cacoub P, Valla D. Biomedicines. 2022 Mar 17;10(3):699. doi: 10.3390/biomedicines10030699.

View Publication

Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).

Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, Terrault NA, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network. Aliment Pharmacol Ther. 2022 Mar 17. doi: 10.1111/apt.16874.

View Publication

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.

Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Lancet Oncol. 2022 Mar 4:S1470-2045(22)00078-X. doi: 10.1016/S1470-2045(22)00078-X.

View Publication

Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.

Castillo-Leon E, Morris HL, Schoen C, Bilhartz J, McKiernan P, Miloh T, Palle S, Kabbany MN, Munoz B, Mospan AR, Rudolph B, Xanthakos SA, Vos MB, Target-Nash Investigators. Children (Basel). 2022 Mar 8;9(3):374. doi: 10.3390/children9030374.

View Publication

Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.

Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16879.

View Publication

NAFLD increases Risk of Carotid Atherosclerosis and Ischemic Stroke. An Updated Meta-Analysis with 135,602 Individuals.

Tang ASP, Chan KE, Quek J, Xiao J, Tay P, Teng M, Lee KS, Lin SY, Myint MZ, Tan B, Sharma VK, Tan DJH, Lim WH, Kaewdech A, Huang D, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M, Ng CH. Clin Mol Hepatol. 2022 Mar 2. doi: 10.3350/cmh.2021.0406.

View Publication

Global multi-stakeholder endorsement of the MAFLD definition.

Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2022 Mar 3:S2468-1253(22)00062-0. doi: 10.1016/S2468-1253(22)00062-0.

View Publication

A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease.

Pennisi G, Pipitone RM, Cabibi D, Enea M, Romero-Gomez M, Viganò M, Bugianesi E, Wong VW, Fracanzani AL, Sebastiani G, Berzigotti A, Di Salvo F, Giannone AG, La Mantia C, Lupo G, Porcasi R, Vernuccio F, Zito R, Di Marco V, Cammà C, Craxì A, de Ledinghen V, Grimaudo S, Petta S. Liver Int. 2022 Mar 4. doi: 10.1111/liv.15232.

View Publication

Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation.

Gallego-Durán R, Ampuero J, Pastor-Ramírez H, Álvarez-Amor L, Del Campo JA, Maya-Miles D, Montero-Vallejo R, Cárdenas-García A, Pareja MJ, Gato-Zambrano S, Millán R, Del Carmen Rico M, Luque-Sierra A, Gil-Gómez A, Rojas Á, Muñoz-Hernández R, García-Lozano M, Aller R, Andrade RJ, García-Monzón C, Andreola F, Martín F, Jalan R, Romero-Gómez M. Sci Rep. 2022 Mar 1;12(1):3418. doi: 10.1038/s41598-022-06614-9.

View Publication

Association of Obesity, Diabetes, and Alcohol Use With Liver Fibrosis Among US Adults With Hepatitis C Virus Infection.

Migdal AL, Jagannathan R, Qayed E, Cusi K, McCoy RG, Pasquel FJ, Miller LS. JAMA Netw Open. 2022 Mar 1;5(3):e2142282. doi: 10.1001/jamanetworkopen.2021.42282.

View Publication

Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.

Sanyal AJ, Shankar SS, Calle RA, Samir AE, Sirlin CB, Sherlock SP, Loomba R, Fowler KJ, Dehn CA, Heymann H, Kamphaus TN. Nat Med. 2022 Mar;28(3):430-432. doi: 10.1038/s41591-021-01652-8.

View Publication

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease

McGlinchey AJ, Govaere O, Geng D, Ratziu V, Allison M, Bousier J, Petta S, de Oliviera C, Bugianesi E, Schattenberg JM, Daly AK, Hyötyläinen T, Anstee QM, Orešič M. JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477.

View Publication

JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk

Wyne KL, Litwin SE, Cusi K, Guyton JR. J Clin Lipidol. 2022 Mar-Apr;16(2):115-127. doi: 10.1016/j.jacl.2022.03.007.

View Publication

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.

Martínez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martín-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi KBugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Hepatology. 2022 Feb 26. doi: 10.1002/hep.32427.

View Publication

Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients.

Stepanova M, Kabbara K, Mohess D, Verma M, Roche-Green A, AlQahtani S, Ong J, Burra P, Younossi ZM. Hepatol Commun. 2022 Feb 28. doi: 10.1002/hep4.1915.

View Publication

Differential fuel utilization in liver transplant recipients and its relationship with non-alcoholic fatty liver disease.

Siddiqui MS, Patel S, Forsgren M, Bui AT, Shen S, Syed T, Boyett S, Chen S, Sanyal AJ, Wolver S, Kirkman D, Celi FS, Bhati CS. Liver Int. 2022 Feb 7. doi: 10.1111/liv.15178.

View Publication

Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium.

Rinella ME, Satapathy SK, Brandman D, Smith C, Elwir S, Xia J, Gibson M, Figueredo C, Angirekula M, Vanatta JM, Sarwar R, Jiang Y, Gregory D, Agostini T, Ko J, Podila P, Gallo G, Watt KD, Siddiqui MS. Clin Gastroenterol Hepatol. 2022 Feb 18:S1542-3565(22)00184-7. doi: 10.1016/j.cgh.2022.02.028.

View Publication

Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease.

Karl M, Hasselwander S, Zhou Y, Reifenberg G, Kim YO, Park KS, Ridder DA, Wang X, Seidel E, Hövelmeyer N, Straub BK, Li H, Schuppan D, Xia N. Hepatology. 2022 Feb 26. doi: 10.1002/hep.32428.

View Publication

Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD.

Tamaki N, Imajo K, Sharpton SR, Jung J, Sutter N, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Kurosaki M, Izumi N, Nakajima A, Loomba R. Clin Gastroenterol Hepatol. 2022 Feb 2:S1542-3565(22)00077-5. doi: 10.1016/j.cgh.2022.01.023.

View Publication

Meaning of non-overlapping patients between the MAFLD and NAFLD definitions.

Chan WK, Wong VW. Liver Int. 2022 Feb;42(2):271-273. doi: 10.1111/liv.15142.

View Publication

Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis.

Younossi ZM, Henry L. Endocr Pract. 2022 Feb;28(2):204-213. doi: 10.1016/j.eprac.2021.12.010. Epub 2021 Dec 22.

View Publication

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.

Johnson K, Leary PJ, Govaere O, Barter MJ, Charlton SH, Cockell SJ, Tiniakos D, Zatorska M, Bedossa P, Brosnan MJ, Cobbold JF, Ekstedt M, Aithal GP, Clément K, Schattenberg JM, Boursier J, Ratziu VBugianesi E, Anstee QM, Daly AK; LITMUS Consortium Investigators; LITMUS Consortium Investigators. JHEP Rep. 2021 Nov 25;4(2):100409. doi: 10.1016/j.jhepr.2021.100409. eCollection 2022 Feb.

View Publication

Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD.

Natarajan Y, Loomba R. J Clin Exp Hepatol. 2022 Jan-Feb;12(1):174-179. doi: 10.1016/j.jceh.2021.08.002.

View Publication

Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.

Tamaki N, Ajmera V, Loomba R. Nat Rev Endocrinol. 2022 Jan;18(1):55-66. doi: 10.1038/s41574-021-00584-0.

View Publication

Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.

Tan EX, Lee JW, Jumat NH, Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Lesmana LA, Zheng KI, Zheng MH, Koh CJ, Ho KY, Goh KL, Wong VW, Dan YY. Metabolism. 2022 Jan;126:154911. doi: 10.1016/j.metabol.2021.154911.

View Publication

Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation.

Foglia B, Sutti S, Cannito S, Rosso C, Maggiora M, Autelli R, Novo E, Bocca C, Villano G, Ramavath NN, Younes R, Tusa I, Rovida E, Pontisso P, Bugianesi E, Albano E, Parola M. Cell Mol Gastroenterol Hepatol. 2021 Oct 14:S2352-345X(21)00216-2. doi: 10.1016/j.jcmgh.2021.10.002.

View Publication

Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.

Duseja A, Singh SP, Mehta M, Shalimar, Venkataraman J, Mehta V, Devadas K, Kar SK, Goyal O, Nagral A, Saigal S, Nijhawan S, Praharaj D, Shukla A, Sharma B, Narayanasamy K, Kumar P, Rao PN, Arora A, Mehta R, Asati P, Ranjan P, Koshy A, Alam S, Mukewar S, Mukewar S, Mohan Prasad VG, Rastogi M, Sanyal AJ. Metab Syndr Relat Disord. 2022 Jan 25. doi: 10.1089/met.2021.0104.

View Publication

Long-Term Effects of the Changes in Hepatic Steatosis Status on the Risk of Incident Type 2 Diabetes Mellitus: a 15-Year Community-Based Prospective Cohort Study.

Min Chung S, Kyu Kang M, Jung J, Sung Yoon J, Chang Won K, Woo Lee H, Loomba R, Gil Park J, Sung Moon J. Diabetes Res Clin Pract. 2022 Jan 18:109208. doi: 10.1016/j.diabres.2022.109208.

View Publication

Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.

Di Maira G, Foglia B, Napione L, Turato C, Maggiora M, Sutti S, Novo E, Alvaro M, Autelli R, Colombatto S, Bussolino F, Carucci P, Gaia S, Rosso C, Biasiolo A, Pontisso P, Bugianesi E, Albano E, Marra F, Parola M, Cannito S. J Pathol. 2022 Jan 22. doi: 10.1002/path.5871.

View Publication

Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis.

Labenz C, Toenges G, Zheng MH, Ding D, Myers RP, Galle PR, Armandi A, Ampuero J, Gómez MR, Bugianesi E, Anstee QM, Schattenberg JM. Eur J Intern Med. 2022 Jan 17:S0953-6205(21)00413-1. doi: 10.1016/j.ejim.2021.12.011.

View Publication

Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.

Boursier J, Hagström H, Ekstedt M, Moreau C, Bonacci M, Cure S, Ampuero J, Nasr P, Tallab L, Canivet CM, Kechagias S, Sánchez Y, Dincuff E, Lucena A, Roux M, Riou J, Trylesinski A, Romero-Gomez M. J Hepatol. 2022 Jan 18:S0168-8278(22)00002-2. doi: 10.1016/j.jhep.2021.12.031.

View Publication

Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.

Pennisi G, Enea M, Romero-Gomez M, Viganò M, Bugianesi E, Wong VW, Fracanzani AL, Sebastiani G, Boursier J, Berzigotti A, Eslam M, Ampuero J, Benmassaoud A, La Mantia C, Mendoza YP, George J, Craxì A, Camma' C, de Ledinghen V, Petta S. Aliment Pharmacol Ther. 2022 Jan 5. doi: 10.1111/apt.16763.

View Publication

Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.

Ng CH, Xiao J, Lim WH, Chin YH, Yong JN, Tan DJH, Tay P, Syn N, Foo R, Chan M, Chew N, Tan EX, Huang DQ, Dan YY, Tamaki N, Siddiqui MS, Sanyal AJLoomba R, Noureddin M, Muthiah MD. Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.

View Publication

NASHFit: of an exercise training program to reduce clotting risk in patients with NASH.

Stine JG, Schreibman IR, Faust AJ, Dahmus J, Stern B, Soriano C, Rivas G, Hummer B, Kimball SR, Geyer NR, Chinchilli VM, Loomba R, Schmitz K, Sciamanna C. Hepatology. 2021 Dec 10. doi: 10.1002/hep.32274.

View Publication

The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, Ekstedt M, Esmat G, George J, Marchesini G, Novak K, Ocama P, Ratziu V, Razavi H, Romero-Gómez M, Silva M, Spearman CW, Tacke F, Tsochatzis EA, Yilmaz Y, Younossi ZM, Wong VW, Zelber-Sagi S, Cortez-Pinto H, Anstee QM; NAFLD policy review collaborators. J Hepatol. 2021 Dec 8:S0168-8278(21)02168-1. doi: 10.1016/j.jhep.2021.10.025.

View Publication

Elevated liver enzymes and comorbidities in type 2 diabetes: Multicenter analysis of 51,645 patients of the DPV database.

Meyhöfer S, Eckert AJ, Hummel M, Laimer M, Roden M, Kress S, Seufert J, Meyhöfer SM, Holl RW. Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14616. Online ahead of print.PMID: 34882949 

View Publication

Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease.

Zhang YN, Fowler KJ, Boehringer AS, Montes V, Schlein AN, Covarrubias Y, Wolfson T, Hong CW, Valasek MA, Andre MP, Loomba R, Sirlin CB. Eur Radiol. 2021 Dec 2. doi: 10.1007/s00330-021-08369-9.

View Publication

An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.

Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. Clin Gastroenterol Hepatol. 2021 Dec 3:S1542-3565(21)01276-3. doi: 10.1016/j.cgh.2021.11.038.

View Publication

Evaluation of a Stepped Care Approach to Manage Depression and Diabetes Distress in Patients with Type 1 Diabetes and Type 2 Diabetes: Results of a Randomized Controlled Trial (ECCE HOMO Study).

Schmitt A, Kulzer B, Reimer A, Herder C, Roden M, Haak T, Hermanns N. Psychother Psychosom. 2021 Dec 7:1-16. doi: 10.1159/000520319.

View Publication

The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.

Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. Lancet. 2021 Dec 1:S0140-6736(21)01701-3. doi: 10.1016/S0140-6736(21)01701-3.

View Publication

Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready-to-use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males.

Hompesch M, Hawryluk A, Hernandez M, Uchil B, Wilmington A, Peterson L. Diabetes Obes Metab. 2021 Dec;23(12):2679-2686. doi: 10.1111/dom.14520.

View Publication

Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply.

Flint A, Andersen G, Hockings P, Plum-Mörschel L, Loomba R. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1498. doi: 10.1111/apt.16669.

View Publication

Corrigendum to ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’ [J Hepatol 75 (2021) 865-878].

Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM. J Hepatol. 2021 Dec;75(6):1515. doi: 10.1016/j.jhep.2021.09.014.

View Publication

Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis.

Kim HP, Idowu MO, Mospan AR, Allmon AG, Roden M, Newsome P, Lok AS, Thuluvath PJ, Taunk J, Fried MW, Sanyal AJ, Barritt AS 4th; TARGET-NASH Investigators. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1472-1480. doi: 10.1111/apt.16674.

View Publication

A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach.

Lazarus JV, Mark HE, Colombo M, Demaio S, Dillon JF, George J, Hagström H, Hocking S, Lee N, Nieuwenhuijsen MJ, Rinella ME, Romero-Gomez M, Soriano JB, Schattenberg JM, Tacke F, Tsochatzis EA, Valenti L, Zelber-Sagi S, Ashworth Dirac M, Huang TT. Aliment Pharmacol Ther. 2021 Dec 5. doi: 10.1111/apt.16720.

View Publication

A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy.

Guo F, Estévez-Vázquez O, Benedé-Ubieto R, Maya-Miles D, Zheng K, Gallego-Durán R, Rojas Á, Ampuero J, Romero-Gómez M, Philip K, Egbuniwe IU, Chen C, Simon J, Delgado TC, Martínez-Chantar ML, Sun J, Reissing J, Bruns T, Lamas-Paz A, Moral MGD, Woitok MM, Vaquero J, Regueiro JR, Liedtke C, Trautwein C, Bañares R, Cubero FJ, Nevzorova YA. Cancers (Basel). 2021 Dec 31;14(1):192. doi: 10.3390/cancers14010192.

View Publication

Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.

Govaere O, Petersen SK, Martinez-Lopez N, Wouters J, Van Haele M, Mancina RM, Jamialahmadi O, Bilkei-Gorzo O, Lassen PB, Darlay R, Peltier J, Palmer JM, Younes R, Tiniakos D, Aithal GP, Allison M, Vacca M, Göransson M, Berlinguer-Palmini R, Clark JE, Drinnan MJ, Yki-Järvinen H, Dufour JF, Ekstedt M, Francque S, Petta S, Bugianesi E, Schattenberg JM, Day CP, Cordell HJ, Topal B, Clément K, Romeo S, Ratziu V, Roskams T, Daly AK, Anstee QM, Trost M, Härtlova A. J Hepatol. 2021 Dec 20:S0168-8278(21)02254-6. doi: 10.1016/j.jhep.2021.12.012.

View Publication

Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.

Graupera I, Thiele M, Serra-Burriel M, Caballeria L, Roulot D, Wong GL, Fabrellas N, Guha IN, Arslanow A, Expósito C, Hernández R, Aithal GP, Galle PR, Pera G, Wong VW, Lammert F, Ginès P, Castera L, Krag A; Investigators of the LiverScreen Consortium. Clin Gastroenterol Hepatol. 2021 Dec 29:S1542-3565(21)01358-6. doi: 10.1016/j.cgh.2021.12.034.

View Publication

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.

Fouqueray P, Bolze S, Dubourg J, Hallakou-Bozec S, Theurey P, Grouin JM, Chevalier C, Gluais-Dagorn P, Moller DE, Cusi K. Cell Rep Med. 2021 Dec 21;2(12):100474. doi: 10.1016/j.xcrm.2021.100474.

View Publication

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.

Loomba R, Ratziu V, Harrison SA; NASH Clinical Trial Design International Working Group. Gastroenterology. 2021 Nov 22:S0016-5085(21)03795-1. doi: 10.1053/j.gastro.2021.10.051.

View Publication

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.

Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Front Immunol. 2021 Nov 24;12:667354. doi: 10.3389/fimmu.2021.667354.

View Publication

Evaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allograft and Nonalcoholic Steatohepatitis.

Brubaker AL, Loomba R. Liver Transpl. 2021 Nov 22. doi: 10.1002/lt.26371.

View Publication

Fatty Liver Disease: Diagnosis and Stratification.

Saiman Y, Duarte-Rojo A, Rinella ME. Annu Rev Med. 2021 Nov 22. doi: 10.1146/annurev-med-042220-020407.

View Publication

Outcomes of Non-alcoholic Steatohepatitis following Liver Transplantation. An Updated Meta-analysis and Systematic Review.

Yong JN, Lim WH, Ng CH, Hao Tan DJ, Xiao J, Lin Tay PW, Lin SY, Syn N, Chew N, Nah B, Dan YY, Huang DQ, Xuan Tan EX, Sanyal AJ, Noureddin M, Siddiqui MS, Muthiah MD. Clin Gastroenterol Hepatol. 2021 Nov 18:S1542-3565(21)01226-X. doi: 10.1016/j.cgh.2021.11.014.

View Publication

Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes.

Maalmi H, Herder C, Bönhof GJ, Strassburger K, Zaharia OP, Rathmann W, Burkart V, Szendroedi J, Roden M, Ziegler D; GDS Group. Diabetologia. 2021 Nov 20. doi: 10.1007/s00125-021-05607-z.

View Publication

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. J Hepatol. 2021 Nov 15:S0168-8278(21)02177-2. doi: 10.1016/j.jhep.2021.10.029.

View Publication

Liquid biomarkers for fibrotic NASH – progress in a complex field.

Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Ann Hepatol. 2021 Nov 18;27(1):100556. doi: 10.1016/j.aohep.2021.100556.

View Publication

Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C.

Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Ann Hepatol. 2021 Nov 18;27(1):100556. doi: 10.1016/j.aohep.2021.100556.

View Publication

Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm.

Danis N, Weeks SR, Kim A, Baghdadi A, Ghadimi M, Kamel IR, Saberi B, Woreta T, Garonzik-Wang J, Philosophe B, Gurakar A, Loomba R. Liver Transpl. 2021 Nov 9. doi: 10.1002/lt.26365.

View Publication

The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review.

Armandi A, Rosso C, Caviglia GP, Ribaldone DG, Bugianesi E. Front Endocrinol (Lausanne). 2021 Nov 10;12:716533. doi: 10.3389/fendo.2021.716533.

View Publication

Comparison of patient characteristics between East Asian and non-East Asian patients with insulin autoimmune syndrome.

Oest L, Roden M, Müssig K. Clin Endocrinol (Oxf). 2021 Nov 14. doi: 10.1111/cen.14634.

View Publication

Physical fitness and cardiovascular risk factors in the novel diabetes subgroups.

Saatmann N, Zaharia OP, Strassburger K, Pesta DH, Burkart V, Szendroedi J, Gerdes N, Kelm M, Roden M. J Clin Endocrinol Metab. 2021 Nov 8:dgab810. doi: 10.1210/clinem/dgab810.

View Publication

Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry.

Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M Sr, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clin Gastroenterol Hepatol. 2021 Nov 9:S1542-3565(21)01183-6. doi: 10.1016/j.cgh.2021.11.004.

View Publication

Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.

Mowry CJ, Alonso C, Iruarrizaga-Lejarreta M, Ortiz P, Levitsky J, Rinella M. Transplant Direct. 2021 Nov 5;7(12):e784. doi: 10.1097/TXD.0000000000001227.

View Publication

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049.

View Publication

EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.

Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. J Hepatol. 2021 Nov 2:S0168-8278(21)02155-3. doi: 10.1016/j.jhep.2021.10.018.

View Publication

The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.

Lewinska M, Santos-Laso A, Arretxe E, Alonso C, Zhuravleva E, Jimenez-Agüero R, Eizaguirre E, Pareja MJ, Romero-Gómez M, Arrese M, Suppli MP, Knop FK, Oversoe SK, Villadsen GE, Decaens T, Carrilho FJ, de Oliveira CP, Sangro B, Macias RIR, Banales JM, Andersen JB. EBioMedicine. 2021 Nov;73:103661. doi: 10.1016/j.ebiom.2021.103661.

View Publication

The peroxisomal transporter ABCD3 plays a major role in hepatic dicarboxylic fatty acid metabolism and lipid homeostasis.

Ranea-Robles P, Chen H, Stauffer B, Yu C, Bhattacharya D, Friedman SL, Puchowicz M, Houten SM. J Inherit Metab Dis. 2021 Nov;44(6):1419-1433. doi: 10.1002/jimd.12440.

View Publication

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.

Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, Meroni M, Graham MJ, Yates KP, Diehl AM, Schwabe RF, Tabas I, Valenti L, Lavine JE, Pajvani UB.
Sci Transl Med. 2018 Nov 21;10(468). pii: eaat0344. doi: 10.1126/scitranslmed.aat0344.

View Publication

Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies.

Schlesinger S, Neuenschwander M, Barbaresko J, Lang A, Maalmi H, Rathmann W, Roden M, Herder C. Diabetologia. 2021 Oct 31. doi: 10.1007/s00125-021-05592-3.   

View Publication

Dietary palmitate and oleate differently modulate insulin sensitivity in human skeletal muscle.

Sarabhai T, Koliaki C, Mastrototaro L, Kahl S, Pesta D, Apostolopoulou M, Wolkersdorfer M, Bönner AC, Bobrov P, Markgraf DF, Herder C, Roden M. Diabetologia. 2021 Oct 26. doi: 10.1007/s00125-021-05596-z.

View Publication

Advancing the global public health agenda for NAFLD: a consensus statement.

Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Nat Rev Gastroenterol Hepatol. 2021 Oct 27. doi: 10.1038/s41575-021-00523-4.

View Publication

Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis.

Bhattacharya D, Becker C, Readhead B, Goossens N, Novik J, Fiel MI, Cousens LP, Magnusson B, Backmark A, Hicks R, Dudley JT, Friedman SL. Sci Rep. 2021 Oct 21;11(1):20827. doi: 10.1038/s41598-021-99008-2.

View Publication

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.

View Publication

Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection.

Khalili M, King WC, Kleiner DE, Chung RT, Bhan AK, Ghany MG, Sulkowski MS, Lisker-Melman M, Jain MK, Janssen HLA, Hinerman AS, Sanyal AJ, Sterling RK. Clin Infect Dis. 2021 Oct 25:ciab764. doi: 10.1093/cid/ciab764.

View Publication

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJLoomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.

View Publication

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.

Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, Loomba R, Chalasani N, Kowdley K, Hameed B, Wilson LA, Yates KP, Belt P, Lazo M, Kleiner DE, Behling C, Tonascia J; NASH Clinical Research Network (CRN). N Engl J Med. 2021 Oct 21;385(17):1559-1569. doi: 10.1056/NEJMoa2029349.

View Publication

Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.

Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.

View Publication

Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong.

Luk AOY, Yip TCF, Zhang X, Kong APS, Wong VW, Ma RCW, Wong GL. BMJ Open. 2021 Oct 20;11(10):e052310. doi: 10.1136/bmjopen-2021-052310.

View Publication

Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease.

Sharpton SR, Tamaki N, Bettencourt R, Madamba E, Jung J, Liu A, Behling C, Valasek MA, Loomba R. Therap Adv Gastroenterol. 2021 Oct 8;14:17562848211050436. doi: 10.1177/17562848211050436. eCollection 2021.

View Publication

The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States.

Younossi ZM, Harring M, Younossi Y, Ong JP, Alqahtani SA, Stepanova M. Clin Gastroenterol Hepatol. 2021 Oct 16:S1542-3565(21)01131-9. doi: 10.1016/j.cgh.2021.10.018.

View Publication

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.

Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S; ARREST investigator study group, Sanyal AJ. Nat Med. 2021 Oct;27(10):1825-1835. doi: 10.1038/s41591-021-01495-3.

View Publication

Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.

Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.

View Publication

Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.

Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.

View Publication

Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis.

Zhang H, Ma Y, Cheng X, Wu D, Huang X, Chen B, Ren Y, Jiang W, Tang X, Bai T, Chen Y, Zhao Y, Zhang C, Xiao X, Liu J, Deng Y, Ye T, Chen L, Liu HM, Friedman SL, Chen L, Ding BS, Cao Z. Sci Transl Med. 2021 Oct 6;13(614):eabd1206. doi: 10.1126/scitranslmed.abd1206.

View Publication

Asian perspective on NAFLD-associated HCC.

Yip TC, Lee HW, Chan WK, Wong GL, Wong VW. J Hepatol. 2021 Oct 4:S0168-8278(21)02086-9. doi: 10.1016/j.jhep.2021.09.024.

View Publication

Association of genetic variations with NAFLD in lean individuals.

Lin H, Wong GL, Whatling C, Chan AW, Leung HH, Tse CH, Shu SS, Chim AM, Lai JC, Yip TC, Wong VW. Liver Int. 2021 Oct 5. doi: 10.1111/liv.15078.

View Publication

Randomized clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.

Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L. Aliment Pharmacol Ther. 2021 Sep 27. doi: 10.1111/apt.16608.

View Publication

Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.

Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Obesity (Silver Spring). 2021 Sep 23. doi: 10.1002/oby.23263.

View Publication

A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Non-alcoholic Fatty Liver Disease.

Kai Toh JZ, Pan XH, Lin Tay PW, Ng CH, Yong JN, Xiao J, Koh JH, Tan EY, Xuan Tan EX, Dan YY, Loh PH, Foo R, Chew NW, Sanyal AJ, Muthiah MD, Siddiqui MS. Clin Gastroenterol Hepatol. 2021 Sep 21:S1542-3565(21)01035-1. doi: 10.1016/j.cgh.2021.09.021.

View Publication

Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review.

Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Expert Rev Gastroenterol Hepatol. 2021 Sep 21:1-14. doi: 10.1080/17474124.2021.1974295.

View Publication

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Lancet Gastroenterol Hepatol. 2021 Sep 21:S2468-1253(21)00300-9. doi: 10.1016/S2468-1253(21)00300-9.

View Publication

Cross-Talk Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: Implications for Future Trial Design.

Pellicori P, Vaduganathan M, Ferreira OP, Zannad F, Sanyal AJ. Diabetes Metab. 2021 Sep 17:101281. doi: 10.1016/j.diabet.2021.101281.

View Publication

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.

Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, Nojima T, Tanigawa R, Iizuka M, Iida Y, Loomba R. Aliment Pharmacol Ther. 2021 Sep 16. doi: 10.1111/apt.16596.

View Publication

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?

Alkhouri N, Tincopa M, Loomba R, Harrison SA. Hepatol Commun. 2021 Sep 9. doi: 10.1002/hep4.1814.

View Publication

MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-related fibrosis.

Tamaki N, Imajo K, Sharpton S, Jung J, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. Hepatology. 2021 Sep 8. doi: 10.1002/hep.32145.

View Publication

Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies.

Lee YA, Friedman SL. J Intern Med. 2021 Sep 26. doi: 10.1111/joim.13380.

View Publication

Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study.

Chan TT, Tse YK, Lui RN, Wong GL, Chim AM, Kong AP, Woo J, Yeung DK, Abrigo JM, Chu WC, Wong VW, Tang RS. Clin Gastroenterol Hepatol. 2021 Sep 25:S1542-3565(21)01041-7. doi: 10.1016/j.cgh.2021.09.027.

View Publication

A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.

Bosch J, Chung C, Carrasco-Zevallos OM, Harrison SA, Abdelmalek MF, Shiffman ML, Rockey DC, Shanis Z, Juyal D, Pokkalla H, Le QH, Resnick M, Montalto M, Beck AH, Wapinski I, Han L, Jia C, Goodman Z, Afdhal N, Myers RP, Sanyal AJ. Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.

View Publication

Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.

Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Clin Gastroenterol Hepatol. 2021 Jul 27:S1542-3565(21)00821-1. doi: 10.1016/j.cgh.2021.07.039.

View Publication

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. Gastroenterology. 2021 Jul 20:S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.

View Publication

Novel Antidiabetic Strategies and Diabetologists’ Views in Nonalcoholic Steatohepatitis.

Kahl S, Pützer J, Roden M. Semin Liver Dis. 2021 Jul 21. doi: 10.1055/s-0041-1732354.

View Publication

Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.

Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, Schattenberg JM, Barritt AS, Noureddin M, Bonacci M, Cawkwell G, Wong B, Rinella M; REGENERATE Study Investigators. Clin Gastroenterol Hepatol. 2021 Jul 15:S1542-3565(21)00751-5. doi: 10.1016/j.cgh.2021.07.020.

View Publication

Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease.

Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N; MRCH Liver Study Group, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J. Clin Gastroenterol Hepatol. 2021 Jul 16:S1542-3565(21)00752-7. doi: 10.1016/j.cgh.2021.07.021.

View Publication

Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD.

Vilarinho S, Ajmera V, Zheng M, Loomba R. Hepatology. 2021 Jul 7. doi: 10.1002/hep.32047.

View Publication

Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis.

Rivera-Esteban J, Armandi A, Augustin S, Bugianesi E.Liver Int. 2021 Jul 9. doi: 10.1111/liv.15013.

View Publication

PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.

Gastaldelli A, Sabatini S, Carli F, Gaggini M, Bril F, Belfort-DeAguiar R, Positano V, Barb D, Kadiyala S, Harrison S, Cusi K. Liver Int. 2021 Jul 5. doi: 10.1111/liv.15005.

View Publication

Preparing for the NASH epidemic: A call to action.

Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Metabolism. 2021 Jul 6:154822. doi: 10.1016/j.metabol.2021.154822.

View Publication

A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.

Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguchi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clin Gastroenterol Hepatol. 2021 Jul 3:S1542-3565(21)00719-9. doi: 10.1016/j.cgh.2021.06.048.

View Publication

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. 
Gastroenterology. 2021 Jul 20:S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.

View Publication

Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes.

Bril F, McPhaul MJ, Kalavalapalli S, Lomonaco R, Barb D, Gray ME, Shiffman D, Rowland CM, Cusi K. J Clin Endocrinol Metab. 2021 Jun 30:dgab417. doi: 10.1210/clinem/dgab417.

View Publication

Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis.

Yu J, Zhu C, Wang X, Kim K, Bartolome A, Dongiovanni P, Yates KP, Valenti L, Carrer M, Sadowski T, Qiang L, Tabas I, Lavine JE, Pajvani UB. Sci Transl Med. 2021 Jun 23;13(599):eabe1692. doi: 10.1126/scitranslmed.abe1692.

View Publication

Defining comprehensive models of care for NAFLD.

Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Nat Rev Gastroenterol Hepatol. 2021 Jun 25. doi: 10.1038/s41575-021-00477-7.

View Publication

Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD.

Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. Physiol Genomics. 2021 Jun 21. doi: 10.1152/physiolgenomics.00011.2021.

View Publication

Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease.

Zhou YJ, Gao F, Liu WY, Wong GL, Mahadeva S, Raihan Nik Mustapha N, Wang XD, Chan WK, Wong VW, Zheng MH. Aliment Pharmacol Ther. 2021 Jun 21. doi: 10.1111/apt.16487.

View Publication

Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.

Dayton KA, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi K. PLoS One. 2021 Jun 2;16(6):e0251449. doi: 10.1371/journal.pone.0251449.

View Publication

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. J Hepatol. 2021 Jun 3:S0168-8278(21)00343-3. doi: 10.1016/j.jhep.2021.05.008.

View Publication

Natural history of NASH.

Armandi A, Bugianesi E. Liver Int. 2021 Jun;41 Suppl 1:78-82. doi: 10.1111/liv.14910.

View Publication

Non-alcoholic fatty liver disease in type 2 diabetes – A specific entity?

Schröder B, Kahl S, Roden M. Liver Int. 2021 Jun;41 Suppl 1:105-111. doi: 10.1111/liv.14846.

View Publication

Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need.

Zhou YJ, Wong VW, Zheng MH. Hepatobiliary Surg Nutr. 2021 Jun;10(3):388-390. doi: 10.21037/hbsn-21-80.

View Publication

New drugs for NASH.

Albhaisi SAM, Sanyal AJ. Liver Int. 2021 Jun;41 Suppl 1:112-118. doi: 10.1111/liv.14844.

View Publication

Management of NAFLD patients with advanced fibrosis.

Maya-Miles D, Ampuero J, Gallego-Durán R, Dingianna P, Romero-Gómez M. Liver Int. 2021 Jun;41 Suppl 1:95-104. doi: 10.1111/liv.14847.PMID: 34155801

View Publication

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.

Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun.

View Publication

Non-alcoholic fatty liver disease.

Powell EE, Wong VWRinella M. Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3.

View Publication

Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.

Dayton KA, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi K. PLoS One. 2021 Jun 2;16(6):e0251449. doi: 10.1371/journal.pone.0251449.

View Publication

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. J Hepatol. 2021 Jun 3:S0168-8278(21)00343-3. doi: 10.1016/j.jhep.2021.05.008.

View Publication

The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography.

Ajmera V, Liu A, Bettencourt R, Dhar D, Richards L, Loomba R. Aliment Pharmacol Ther. 2021 Jul;54(1):68-77. doi: 10.1111/apt.16392. Epub 2021 May 11.

View Publication

Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model.

Funuyet-Salas J, Martín-Rodríguez A, Pérez-San-Gregorio MÁ, Romero-Gómez M. J Clin Med. 2021 May 20;10(10):2208. doi: 10.3390/jcm10102208.

View Publication

The Burden of Nonalcoholic Fatty Liver Disease in Asia, Middle East and North Africa: Data from Global Burden of Disease 2009-2019.

Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. J Hepatol. 2021 May 31:S0168-8278(21)00358-5. doi: 10.1016/j.jhep.2021.05.022.

View Publication

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.

Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lupșor-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Yılmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geier A, Tuthill T, Brosnan MJ, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Gut. 2021 May 17:gutjnl-2021-324243. doi: 10.1136/gutjnl-2021-324243.

View Publication

Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Cancers (Basel). 2021 May 11;13(10):2305. doi: 10.3390/cancers13102305.

View Publication

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis.

Selvaraj EA, Mózes FE, Ajmer Jayaswal AN, Zafarmand MH, Vali Y, Lee JA, Levick CK, Joseph Young LA, Palaniyappan N, Liu CH, Aithal GP, Romero-Gómez M, Brosnan MJ, Tuthill TA, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. J Hepatol. 2021 May 12:S0168-8278(21)00309-3. doi: 10.1016/j.jhep.2021.04.044.

View Publication

Mechanisms and disease consequences of nonalcoholic fatty liver disease.

Loomba R, Friedman SL, Shulman GI. Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.

View Publication

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis.

Albhaisi S, Sanyal AJ. Front Endocrinol (Lausanne). 2021 May 10;12:665987. doi: 10.3389/fendo.2021.665987.

View Publication

Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.

Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Semin Liver Dis. 2021 May;41(2):191-205. doi: 10.1055/s-0041-1723752.

View Publication

Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study.

Chiyanika C, Wong VW, Wong GL, Chan HL, Hui SCN, Yeung DKW, Chu WCW. Clin Transl Gastroenterol. 2021 Feb 17;12(2):e00300. doi: 10.14309/ctg.0000000000000300.

View Publication

Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.

Alqahtani SA, Golabi P, Paik JM, Lam B, Moazez AH, Elariny HA, Goodman Z, Younossi ZM. Obes Surg. 2021 Feb 22. doi: 10.1007/s11695-020-04996-1.

View Publication

A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.

Taylor-Weiner A, Pokkalla H, Han L, Jia C, Huss R, Chung C, Elliott H, Glass B, Pethia K, Carrasco-Zevallos O, Shukla C, Khettry U, Najarian R, Taliano R, Subramanian GM, Myers RP, Wapinski I, Khosla A, Resnick M, Montalto MC, Anstee QM, Wong VW, Trauner M, Lawitz EJ, Harrison SA, Okanoue T, Romero-Gomez M, Goodman Z, Loomba R, Beck AH, Younossi ZM. Hepatology. 2021 Feb 11. doi: 10.1002/hep.31750.

View Publication

Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in five european countries in 2018: A cost-of-illness analysis.

Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugianesi E, Romero-Gomez M, Bantel H, Ryder SD, Boursier J, Leroy V, Crespo J, Castera L, Floros L, Atella V, Mestre-Ferrandiz J, Elliott R, Kautz A, Morgan A, Hartmanis S, Vasudevan S, Pezzullo L, Trylesinski A, Cure S, Higgins V, Ratziu V. Liver Int. 2021 Feb 15. doi: 10.1111/liv.14825.

View Publication

Therapeutic pipeline in nonalcoholic steatohepatitis.

Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2021 Feb 10. doi: 10.1038/s41575-020-00408-y.

View Publication

Simple non-invasive scoring systems and histologic scores in predicting mortality in NAFLD patients: A systematic review and meta-analysis.

Liu CH, Ampuero J, Pavlides M, Wong VW, Fan JG, Bai L, Li H, Wu DB, Zhou LY, Du LY, Yang TK, Jiang W, Shi Y, Gil-Gómez A, Zhang WT, Liang JX, Romero-Gómez M, Tang H. J Gastroenterol Hepatol. 2021 Feb 10. doi: 10.1111/jgh.15431.

View Publication

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?

Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, McLeod D, Pareja MJ, Fracanzani AL, Aller R, Rosso C, Ampuero J, Gallego-Durán R, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Birolo G, Fariselli P, Eslam M, Valenti L, George J, Romero-Gómez M, Anstee QM, Bugianesi E. Gut. 2021 Feb 4:gutjnl-2020-322564. doi: 10.1136/gutjnl-2020-322564.

View Publication

Non-invasive Tests to Phenotype Nonalcoholic Fatty Liver Disease – Sequence and Consequences of Arranging the Tools In the Tool Box.

Vuppalanchi R, Loomba R. Hepatology. 2021 Feb 5. doi: 10.1002/hep.31734.

View Publication

Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.

Przybyszewski EM, Targher G, Roden M, Corey KE. Clin Liver Dis (Hoboken). 2021 Feb 1;17(1):19-22. doi: 10.1002/cld.1017.

View Publication

Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: A population -based study.

Julián MT, Pera G, Soldevila B, Caballería L, Julve J, Puig-Jové C, Morillas R, Torán P, Expósito C, Puig-Domingo M, Castelblanco E, Franch-Nadal J, Cusi K, Mauricio D, Alonso N. Eur J Endocrinol. 2021 Feb 1:EJE-20-1240.R1. doi: 10.1530/EJE-20-1240.

View Publication

NAFLD-related HCC.

Banini BA, Sanyal AJ. Adv Cancer Res. 2021;149:143-169. doi: 10.1016/bs.acr.2020.11.001.

View Publication

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, Roden M, Sacks F, Tacke F. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):24-39. doi: 10.1038/s41575-020-00366-5.

View Publication

Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort.

Malespin MH, Barritt AS 4th, Watkins SE, Schoen C, Tincopa MA, Corbin KD, Mospan AR, Munoz B, Trinh HN, Weiss LM, Reddy KR, Loomba R, Kemmer N, Lok AS.Clin Gastroenterol Hepatol. 2021 Jan 21:S1542-3565(21)00073-2. doi: 10.1016/j.cgh.2021.01.023.

View Publication

Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement.

Hagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Grønbaek H, Ismail M, Jepsen P, Kanwal F, Kramer J, Lazarus JV, Long MT, Loomba R, Newsome PN, Rowe IA, Ryu S, Schattenberg JM, Serper M, Sheron N, Simon TG, Tapper EB, Wild S, Wong VW, Yilmaz Y, Zelber-Sagi S, Åberg F. Hepatology. 2021 Jan 23. doi: 10.1002/hep.31726.

View Publication

Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD).

Burz SD, Monnoye M, Philippe C, Farin W, Ratziu V, Strozzi F, Paillarse JM, Chêne L, Blottière HM, Gérard P. Microorganisms. 2021 Jan 19;9(1):199. doi: 10.3390/microorganisms9010199.

View Publication

NAFLD as a metabolic disease in humans: A literature review.

Cariou B, Byrne CD, Loomba R, Sanyal AJ. Diabetes Obes Metab. 2021 Jan 19. doi: 10.1111/dom.14322.

View Publication

Relevance of fructose intake in adolescence for fatty liver indices in young adulthood.

Perrar I, Buyken AE, Penczynski KJ, Remer T, Kuhnle GG, Herder C, Roden M, Della Corte K, Nöthlings U, Alexy U. Eur J Nutr. 2021 Jan 19. doi: 10.1007/s00394-020-02463-2.

View Publication

Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.

Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, de Lédinghen V, Baumeler S, Chan WK, Perlemuter G, Cardoso AC, Aggarwal S, Sasso M, Eddowes PJ, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Cobbold JF, Naveau S, Lupsor-Platon M, Mueller S, Krag A, Irles-Depe M, Semela D, Wong GL, Wong VW, Villela-Nogueira CA, Garg H, Chazouillères O, Wiegand J, Karlas T. Lancet Gastroenterol Hepatol. 2021 Jan 15:S2468-1253(20)30357-5. doi: 10.1016/S2468-1253(20)30357-5.

View Publication

Management of non-alcoholic fatty liver disease.

Petroni ML, Brodosi L, Bugianesi E, Marchesini G. BMJ. 2021 Jan 18;372:m4747. doi: 10.1136/bmj.m4747.

View Publication

Yet more evidence that MAFLD is more than name change.

Eslam M, Ratziu V, George J. J Hepatol. 2021 Jan 13:S0168-8278(21)00008-8. doi: 10.1016/j.jhep.2020.12.025.

View Publication

Imaging Biomarkers of NAFLD, NASH, and Fibrosis.

Ajmera V, Loomba R. Mol Metab. 2021 Jan 15:101167. doi: 10.1016/j.molmet.2021.101167.

View Publication

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis.

Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, Ravaioli F, Palmer J, Petta S, Boursier J, Rosso C, Johnson K, Wonders K, Day CP, Ekstedt M, Orešič M, Darlay R, Cordell HJ, Marra F, Vidal-Puig A, Bedossa P, Schattenberg JM, Clément K, Allison M, Bugianesi E, Ratziu V, Daly AK, Anstee QM. Sci Transl Med. 2020 Dec 2;12(572):eaba4448. doi: 10.1126/scitranslmed.aba4448.

View Publication

Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart.

Cusi K, Godinez Leiva E. Curr Opin Lipidol. 2020 Dec;31(6):364-366. doi: 10.1097/MOL.0000000000000717.

View Publication

Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.

Banini BA, P Kumar D, Cazanave S, Seneshaw M, Mirshahi F, Santhekadur PK, Wang L, Guan HP, Oseini A, Alonso C, Bedossa P, Koduru SV, Min HK, Sanyal AJ. Hepatology. 2020 Nov 1. doi: 10.1002/hep.31609.

View Publication

Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans.

Apostolopoulou M, Gordillo R, Gancheva S, Strassburger K, Herder C, Esposito I, Schlensak M, Scherer PE, Roden M. BMJ Open Diabetes Res Care. 2020 Nov;8(2):e001860. doi: 10.1136/bmjdrc-2020-001860.

View Publication

“The predictive value of significant fibrosis for metabolic disturbances in NAFLD patients”.

Ampuero J, Gallego-Durán R, Romero-Gómez M. J Hepatol. 2020 Dec 24:S0168-8278(20)33895-2. doi: 10.1016/j.jhep.2020.12.020.

View Publication

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.

Afonso MB, Rodrigues PM, Mateus-Pinheiro M, Simão AL, Gaspar MM, Majdi A, Arretxe E, Alonso C, Santos A, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Banales J, Ratziu V, Gautheron J, Castro RE, Rodrigues CM. Gut. 2020 Dec 24:gutjnl-2020-321767. doi: 10.1136/gutjnl-2020-321767.

View Publication

Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension.

Elkrief L, Lazareth M, Chevret S, Paradis V, Magaz M, Blaise L, Rubbia-Brandt L, Moga L, Durand F, Payancé A, Plessier A, Chaffaut C, Valla D, Malphettes M, Diaz A, Nault JC, Nahon P, Audureau E, Ratziu V, Castera L, Garcia Pagan JC, Ganne-Carrie N, Rautou PE; ANRS CO12 CirVir group.Hepatology. 2020 Dec 21. doi: 10.1002/hep.31688.

View Publication

Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes.

Carlier A, Phan F, Szpigel A, Hajduch E, Salem JE, Gautheron J, Le Goff W, Guérin M, Lachkar F, Ratziu V, Hartemann A, Ferré P, Foufelle F, Bourron O. Cell Rep Med. 2020 Dec 22;1(9):100154. doi: 10.1016/j.xcrm.2020.100154.

View Publication

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.

Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N, Cusi K. Diabetes Care. 2020 Dec 21:dc201997. doi: 10.2337/dc20-1997.

View Publication

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Huang DQ, El-Serag HB, Loomba R. Nat Rev Gastroenterol Hepatol. 2020 Dec 21. doi: 10.1038/s41575-020-00381-6.

View Publication

Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease.

Kazankov K, Rosso C, Younes R, Armandi A, Hagström H, Møller HJ, Stål P, Bugianesi E, Grønbæk H. Front Med (Lausanne). 2020 Dec 18;7:616212. doi: 10.3389/fmed.2020.616212.

View Publication

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study.

Doward LC, Balp MM, Twiss J, Slota C, Cryer D, Brass CA, Anstee QM, Sanyal AJ. Patient. 2020 Dec 18. doi: 10.1007/s40271-020-00485-w.

View Publication

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.

Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Medicine (Baltimore). 2020 Dec 11;99(50):e23506. doi: 10.1097/MD.0000000000023506.

View Publication

Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.

Bayoumi A, Jalil I, Metwally M, Adams LA, Aller R, García-Monzón C, Arias-Loste MT, Miele L, Petta S, Craxì A, Gallego-Durán R, Fischer J, Berg T, Qiao L, Liddle C, Bugianesi E, Romero-Gomez M, George J, Eslam M. PLoS One. 2020 Dec 11;15(12):e0243590. doi: 10.1371/journal.pone.0243590.

View Publication

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.

Younossi ZM, Corey KE, Lim JK. Gastroenterology. 2020 Dec 9:S0016-5085(20)35538-4. doi: 10.1053/j.gastro.2020.11.051.

View Publication

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.

Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Medicine (Baltimore). 2020 Dec 11;99(50):e23506. doi: 10.1097/MD.0000000000023506.

View Publication

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials.

Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly TE, Morrow L, Hompesch M, Hellerstein MK, Li K, Johansson L, Kelly PF. Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14272.

View Publication

The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH).

Younossi ZM, Anstee QM, Wai-Sun Wong V, Trauner M, Lawitz EJ, Harrison SA, Camargo M, Kersey K, Subramanian GM, Myers RP, Stepanova M. Gastroenterology. 2020 Dec 8:S0016-5085(20)35529-3. doi: 10.1053/j.gastro.2020.12.003.

View Publication

Non-alcoholic fatty liver disease: Not time for an obituary just yet!

Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. J Hepatol. 2020 Dec 16:S0168-8278(20)33729-6. doi: 10.1016/j.jhep.2020.10.015.

View Publication

Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?

Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. J Hepatol. 2020 Dec 16:S0168-8278(20)33729-6. doi: 10.1016/j.jhep.2020.10.015.

View Publication

Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease.

Mueller NT, Liu T, Mitchel EB, Yates KP, Suzuki A, Behling C, Lavine JE. J Clin Endocrinol Metab. 2020 Nov 1;105(11):dgaa574. doi: 10.1210/clinem/dgaa574.

View Publication

A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients.

Eslam M, Wong GL, Hashem AM, Chan HL, Nielsen MJ, Leeming DJ, Chan AW, Chen Y, Duffin KL, Karsdal M, Schattenberg JM, George J, Wong VW. Am J Gastroenterol. 2020 Nov 26. doi: 10.14309/ajg.0000000000001059.

View Publication

Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus.

Kupriyanova Y, Zaharia OP, Bobrov P, Karusheva Y, Burkart V, Szendroedi J, Hwang JH, Roden M; GDS group. J Hepatol. 2020 Nov 28:S0168-8278(20)33817-4. doi: 10.1016/j.jhep.2020.11.030.

View Publication

Overall clinical and economic impact of non-alcoholic fatty liver disease.

Sicras-Mainar A, Aller R, Crespo J, Calleja JL, Turnes J, Romero-Gómez M, Augustín S. Rev Esp Enferm Dig. 2020 Nov 23. doi: 10.17235/reed.2020.7238/2020.

View Publication

Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.

Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, D'Ambrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele L, Vespasiani-Gentilucci U, Anstee QM, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, Soardo G, Reeves H, Prati D, Romeo S, Valenti L.J Hepatol. 2020 Nov 25:S0168-8278(20)33811-3. doi: 10.1016/j.jhep.2020.11.024.

View Publication

MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.

Jung J,Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, Singh S, Hernandez C, Valasek MA, Behling C, Richards L, Fowler K, Sirlin CB, Nakajima A, Loomba R. Gut. 2020 Nov 19:gutjnl-2020-322976. doi: 10.1136/gutjnl-2020-322976.

View Publication

Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P.

Caviglia GP, Rosso C, Armandi A, Gaggini M, Carli F, Abate ML, Olivero A, Ribaldone DG, Saracco GM, Gastaldelli A, Bugianesi E. Int J Mol Sci. 2020 Nov 22;21(22):E8838. doi: 10.3390/ijms21228838.

View Publication

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2028395.

View Publication

Non-alcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.

Pafili K, Roden M. Mol Metab. 2020 Nov 18:101122. doi: 10.1016/j.molmet.2020.101122.

View Publication

MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis.

Loomba R. Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624.

View Publication

Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice.

Xanthakos SA, Lavine JE, Yates KP, Schwimmer JB, Molleston JP, Rosenthal P, Murray KF, Vos MB, Jain AK, Scheimann AO, Miloh T, Fishbein M, Behling CA, Brunt EM, Sanyal AJ, Tonascia J; NASH Clinical Research Network. Gastroenterology. 2020 Nov;159(5):1731-1751.e10. doi: 10.1053/j.gastro.2020.07.034.

View Publication

Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.

Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N; ATLAS Investigators. Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.

View Publication

Clinical utility of change in nonalcoholic fatty liver disease activity score and change in fibrosis in NAFLD.

Tamaki N, Munaganuru N, Jung J, Yonan AQ, Bettencourt R, Ajmera V, Valasek MA, Behling C, Loomba R. Clin Gastroenterol Hepatol. 2020 Nov 3:S1542-3565(20)31518-4. doi: 10.1016/j.cgh.2020.11.005.

View Publication

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis.

Siddiqui MS, Idowu MO, Parmar D, Borg BB, Denham D, Loo NM, Lazas D, Younes Z, Sanyal AJ. Clin Gastroenterol Hepatol. 2020 Nov 2:S1542-3565(20)31509-3. doi: 10.1016/j.cgh.2020.10.051.

View Publication

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.

Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M, Bedossa P, Betsou F, Boursier J, Brosnan MJ, Burt A, Cobbold J, Cortez-Pinto H, Day CP, Dufour JF, Ekstedt M, Francque S, Harrison S, Miele L, Nasr P, Papatheodoridis G, Petta S, Tiniakos D, Torstenson R, Valenti L, Holleboom AG, Yki-Jarvinen H, Geier A, Romero-Gomez M, Ratziu V, Bugianesi E, Schattenberg JM, Anstee QM; LITMUS Consortium. Contemp Clin Trials. 2020 Oct 9;98:106175. doi: 10.1016/j.cct.2020.106175.

View Publication

3D analysis of microvasculature in murine liver fibrosis models using synchrotron radiation-based microtomography.

Wagner WL, Föhst S, Hock J, Kim YO, Popov Y, Schuppan D, Schladitz K, Redenbach C, Ackermann M. Angiogenesis. 2020 Oct 10. doi: 10.1007/s10456-020-09751-9.

View Publication

Expert Panel Review on Non-Alcoholic Fatty Liver Disease in Persons with HIV.

Lake JE, Overton T, Naggie S, Sulkowski M, Loomba R, Kleiner DE, Price JC, Chew KW, Chung RT, Corey KE. Clin Gastroenterol Hepatol. 2020 Oct 15:S1542-3565(20)31431-2. doi: 10.1016/j.cgh.2020.10.018.

View Publication

Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.

Harrison SA, Calanna S, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal A, Sejling AS, Newsome PN. Contemp Clin Trials. 2020 Oct 8:106174. doi: 10.1016/j.cct.2020.106174.

View Publication

Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.

Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Mendez-Sanchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Ann Hepatol. 2020 Oct 5:S1665-2681(20)30177-0. doi: 10.1016/j.aohep.2020.09.006.

View Publication

In vivo absolute quantification of hepatic γ-ATP concentration in mice using 31 P MRS at 11.7 T.

Rothe M, Wessel C, Cames S, Szendroedi J, Burkart V, Hwang JH, Roden M. NMR Biomed. 2020 Oct 6:e4422. doi: 10.1002/nbm.4422.

View Publication

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. Hepatol Int. 2020 Oct 1. doi: 10.1007/s12072-020-10094-2.

View Publication

Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.

Budd J, Cusi K. Curr Diab Rep. 2020 Oct 5;20(11):59. doi: 10.1007/s11892-020-01349-1.

View Publication

ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.

Calzadilla-Bertot L, Vilar-Gomez E, Wong VW, Romero-Gomez M, Aller-de la Fuente R, Wong GL, Castellanos M, Eslam M, Desai AP, Jeffrey GP, George J, Chalasani N, Adams LA. Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.

View Publication

Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard.

Ajmera VH, Cachay ER, Ramers CB, Bassirian S, Singh S, Bettencourt R, Richards L, Hamilton G, Middleton M, Fowler K, Sirlin C, Loomba R. Clin Infect Dis. 2020 Sep 25:ciaa429. doi: 10.1093/cid/ciaa429.

View Publication

Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease.

Patel S, Siddiqui MB, Roman JH, Zhang E, Lee E, Shen S, Faridnia M, Mintini RJ, Boyett S, Idowu MO, Sanyal AJ, Luketic VA, Siddiqui MS. Clin Gastroenterol Hepatol. 2020 Sep 29:S1542-3565(20)31369-0. doi: 10.1016/j.cgh.2020.09.039.

View Publication

The times they are a-changin’ (for NAFLD as well).

Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, Francque S, Sanyal A, Newsome PN, Younossi Z. J Hepatol. 2020 Sep 2:S0168-8278(20)33599-6. doi: 10.1016/j.jhep.2020.08.028.

View Publication

Dietary Rapeseed Oil Supplementation Reduces Hepatic Steatosis in Obese Men – A Randomized Controlled Trial.

Kruse M, Kemper M, Gancheva S, Osterhoff M, Dannenberger D, Markgraf D, Machann J, Hierholzer J, Roden M, Pfeiffer AFH. Mol Nutr Food Res. 2020 Sep 13:e2000419. doi: 10.1002/mnfr.202000419.

View Publication

Clinical endpoints are necessary in the interim analysis of REGENERATE – Authors’ reply.

Ratziu V, Younossi ZM, Campagna JA, MacConell L, Sanyal AJ. Lancet. 2020 Sep 5;396(10252):663-664. doi: 10.1016/S0140-6736(20)30807-2.

View Publication

A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease.

Maev IV, Samsonov AA, Lazebnik LB, Golovanova EV, Pavlov CS, Vovk EI, Ratziu V, Starostin KM. Adv Ther. 2020 Sep 16. doi: 10.1007/s12325-020-01493-w.

View Publication

CPAP Did Not Improve Nonalcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea: A Randomized Clinical Trial.

Ng SS, Wong VW, Wong GL, Chu WC, Chan TO, To KW, Ko FW, Chan KP, Hui DS. Am J Respir Crit Care Med. 2020 Sep 14. doi: 10.1164/rccm.202005-1868OC.

View Publication

Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts.

Calleja-Panero JL, Andrade RJ, Bañares R, Crespo J, Esteban R, Jarque I, Mingot-Castellano ME, Romero-Gómez M, Muñoz-Peñín R, Bentley R, Shepherd J, Gil Aguirre A. Rev Esp Enferm Dig. 2020 Sep 21;112. doi: 10.17235/reed.2020.6895/2020.

View Publication

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.

Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, Clement S, Basu R, Gordon SC, Ravendhra N, Puri P, Rinella M, Scudera P, Singal AK, Henry L; US Members of the Global Nash Council. Aliment Pharmacol Ther. 2020 Aug;52(3):513-526. doi: 10.1111/apt.15830. Epub 2020 Jun 29.PMID: 32598051

View Publication

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease.

Zheng KI, Fan JG, Shi JP, Wong VW, Eslam M, George J, Zheng MH. Chin Med J (Engl). 2020 Jul 21. doi: 10.1097/CM9.0000000000000981. Online ahead of print.PMID: 32701591 

View Publication

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH.

Hydes TJ, Ravi S, Loomba R, E Gray M. Clin Mol Hepatol. 2020 Jul 17. doi: 10.3350/cmh.2020.0067. Online ahead of print.PMID: 32674529 

View Publication

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

Perdomo C, D'Ingianna P, Escalada J, Petta S, Romero Gómez M, Ampuero J. Pol Arch Intern Med. 2020 Jul 14. doi: 10.20452/pamw.15510. Online ahead of print.PMID: 32666779

View Publication

Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease.

Kim D, Murag S, Cholankeril G, Cheung A, Harrison SA, Younossi ZM, Ahmed A. Clin Gastroenterol Hepatol. 2020 Jul 16:S1542-3565(20)30985-X. doi: 10.1016/j.cgh.2020.07.023. Online ahead of print.PMID: 32683103

View Publication

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.

Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Hepatology. 2020 Jul;72(1):58-71. doi: 10.1002/hep.31205.PMID: 32115759

View Publication

MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.

Han MAT, Vipani A, Noureddin N, Ramirez K, Gornbein J, Saouaf R, Baniesh N, Cummings-John O, Okubote T, Setiawan VW, Rotman Y, Loomba R, Alkhouri N, Noureddin M. Liver Int. 2020 Jul 11. doi: 10.1111/liv.14593. Online ahead of print.PMID: 32652744

View Publication

The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology.

Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Janicko M, Steib C, Reiberger T, Acevedo J, Gatti P, Bernal W, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Bendtsen F, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Özdogan OC, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Curto A, Pitarch C, Putignano A, Moreno E, Shawcross D, Aguilar F, Claria J, Ponzo P, Jansen C, Vitalis Z, Zaccherini G, Balogh B, Vargas V, Montagnese S, Alessandria C, Bernardi M, Ginès P, Jalan R, Moreau R, Angeli P, Arroyo V; PREDICT STUDY group of the EASL-CLIF CONSORTIUM. J Hepatol. 2020 Jul 13:S0168-8278(20)30384-6. doi: 10.1016/j.jhep.2020.06.013. Online ahead of print.PMID: 32673741 

View Publication

Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.

Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernandez-Guerra M, Augustín S, Bañales J, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. J Hepatol. 2020 Jul;73(1):17-25. doi: 10.1016/j.jhep.2020.02.028.

View Publication

Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.

Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B. Gastroenterology. 2020 Jul 8:S0016-5085(20)34923-4. doi: 10.1053/j.gastro.2020.07.005. Online ahead of print.PMID: 32652145

View Publication

Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.

Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Aliment Pharmacol Ther. 2020 Jul 8. doi: 10.1111/apt.15935. Online ahead of print.PMID: 32638417 

View Publication

Real-World Burden of Nonalcoholic Steatohepatitis.

Geier A, Rinella M, Balp MM, McKenna SJ, Brass C, Przybysz R, Cai J, Knight A, Gavaghan M, Howe T, Rosen D, Ratziu V. Clin Gastroenterol Hepatol. 2020 Jul 4:S1542-3565(20)30928-9. doi: 10.1016/j.cgh.2020.06.064. Online ahead of print.PMID: 32634622

View Publication

Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T. J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15172. Online ahead of print.PMID: 32627871 

View Publication

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease.

Petta S, Sebastiani G, Viganò M, Ampuero J, Wai-Sun Wong V, Boursier J, Berzigotti A, Bugianesi E, Fracanzani AL, Cammà C, Enea M, Grottes MD, Di Marco V, Younes R, Keyrouz A, Mazzola S, Mendoza Y, Pennisi G, Romero-Gomez M, Craxì A, de Ledinghen V. Clin Gastroenterol Hepatol. 2020 Jul 1:S1542-3565(20)30908-3. doi: 10.1016/j.cgh.2020.06.045. Online ahead of print.PMID: 32621970

View Publication

Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus.

Bajaj JS, Lauridsen M, Tapper EB, Duarte-Rojo A, Rahimi RS, Tandon P, Shawcross DL, Thabut D, Dhiman RK, Romero-Gomez M, Sharma BC, Montagnese S. Am J Gastroenterol. 2020 Jul;115(7):989-1002. doi: 10.14309/ajg.0000000000000603.PMID: 32618647

View Publication

What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist’s Perspective.

Méndez-Sánchez N, Valencia-Rodríguez A, Qi X, Yoshida EM, Romero-Gómez M, George J, Eslam M, Abenavoli L, Xie W, Teschke R, Carrion AF, Keaveny AP.
J Clin Transl Hepatol. 2020 Jun 28;8(2):0024. doi: 10.14218/JCTH.2020.00024. Epub 2020 Apr 11.

View Publication

Mitochondrial oxidative injury: A key player in nonalcoholic fatty liver disease.

Dornas W, Schuppan D. Am J Physiol Gastrointest Liver Physiol. 2020 Jun 29. doi: 10.1152/ajpgi.00121.2020. Online ahead of print.PMID: 32597705

View Publication

A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.

Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba EV, Bettencourt R, Richards L, Raffatellu M, Dorrestein PC, Yu RT, Atkins AR, Huan T, Brenner DA, Sirlin CB, Knight R, Downes M, Evans RM, Loomba R. Cell Metab. 2020 Jun 30:S1550-4131(20)30306-5. doi: 10.1016/j.cmet.2020.06.005. Online ahead of print.PMID: 32610095

View Publication

Metabolic liver disease in diabetes – From mechanisms to clinical trials.

Dewidar B, Kahl S, Pafili K, Roden M. Metabolism. 2020 Jun 20:154299. doi: 10.1016/j.metabol.2020.154299. Online ahead of print.PMID: 32569680 

View Publication

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.

Loomba R, Morgan E, Watts L, Xia S, Hannan LA, Geary RS, Baker BF, Bhanot S. Lancet Gastroenterol Hepatol. 2020 Jun 15:S2468-1253(20)30186-2. doi: 10.1016/S2468-1253(20)30186-2. Online ahead of print.PMID: 32553151

View Publication

From NAFLD to MAFLD: Implications of a premature change in terminology.

Younossi ZM, Rinella ME, Sanyal A, Harrison SA, Brunt E, Goodman Z, Cohen DE, Loomba R. Hepatology. 2020 Jun 16. doi: 10.1002/hep.31420. Online ahead of print.PMID: 32544255

View Publication

Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients.

Gómez-Hurtado I, Gallego-Durán R, Zapater P, Ampuero J, Aller R, Crespo J, Arias-Loste M, García-Monzón C, Bellot P, González-Rodríguez Á, Juanola O, Romero-Gómez M, Francés R. Liver Int. 2020 Jun 19. doi: 10.1111/liv.14571. Online ahead of print.PMID: 32559006

View Publication

Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong.

Tampi RP, Wong VW, Wong GL, Shu SS, Chan HL, Fung J, Stepanova M, Younossi ZM. Hepatol Res. 2020 Jun 14. doi: 10.1111/hepr.13535. Online ahead of print.PMID: 32537840

View Publication

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.

Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, Sheikh MY, Schattenberg JM, Kayali Z, Zivony A, Sheikh A, Garcia-Samaniego J, Satapathy SK, Therapondos G, Mena E, Schuppan D, Robinson J, Chan JL, Hagerty DT, Sanyal AJ.
J Hepatol. 2020 May;72(5):816-827. doi: 10.1016/j.jhep.2019.11.024. Epub 2019 Dec 27. 

View Publication

Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model.

de Conti A, Tryndyak V, Willett RA, Borowa-Mazgaj B, Watson A, Patton R, Khare S, Muskhelishvili L, Olson GR, Avigan MI, Cerniglia CE, Ross SA, Sanyal AJ, Beland FA, Rusyn I, Pogribny IP.
FASEB J. 2020 Apr 18. doi: 10.1096/fj.202000194R.

View Publication

Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.

Sayiner M, Arshad T, Golabi P, Paik J, Farhat F, Younossi ZM.
Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w.

View Publication

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.

Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT.
Hepatology. 2020 Apr 16. doi: 10.1002/hep.31281.

View Publication

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.

Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, Karanikas CA, Duffin KL, Robins DA, Haupt A.
Diabetes Care. 2020 Apr 14. pii: dc191892. doi: 10.2337/dc19-1892.

View Publication

Have incidence rates of liver cancer peaked in the United States?

Petrick JL, Florio AA, Loomba R, McGlynn KA.
Cancer. 2020 Apr 15. doi: 10.1002/cncr.32794.

View Publication

Longitudinal relationship of amino acids and indole metabolites with long-term body mass index and cardiometabolic risk markers in young individuals.

Oluwagbemigun K, Anesi A, Ulaszewska M, Clarke G, Alexy U, Schmid M, Roden M, Herder C, Mattivi F, Nöthlings U.
Sci Rep. 2020 Apr 14;10(1):6399. doi: 10.1038/s41598-020-63313-z.

View Publication

Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.

Nardo AD, Grün NG, Zeyda M, Dumanic M, Oberhuber G, Rivelles E, Helbich TH, Markgraf DF, Roden M, Claudel T, Trauner M, Stulnig TM.
Liver Int. 2020 Apr 13. doi: 10.1111/liv.14464.

View Publication

A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, Wong VW, Dufour JF, Schattenberg J, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Gronbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J.
J Hepatol. 2020 Apr 8. pii: S0168-8278(20)30201-4. doi: 10.1016/j.jhep.2020.03.039.

View Publication

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.

Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratziu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK; EPoS Consortium Investigators.
J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30213-0. doi: 10.1016/j.jhep.2020.04.003.

View Publication

Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.

Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH; LITMUS systematic review team, Pavlides M, Levick C, Duffin K, Hyde C, Bauer T, Bedossa P, Leeming D, Daly A, Hanf R, Ortiz P, Oresic M, Schuppan D, Hanauer G, Chen Y, Shumbayawonda E, Bjerring PN, Zwinderman K.
J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30198-7. doi: 10.1016/j.jhep.2020.03.036.

View Publication

Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.

Ratziu V.
Hepatology. 2020 Apr;71(4):1146-1149. doi: 10.1002/hep.31213.

View Publication

Modelling NAFLD disease burden in four Asian regions-2019-2030.

Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, Hu TH, Huang JF, Jang BK, Jun DW, Kao JH, Lee JW, Lin HC, Razavi-Shearer K, Seto WK, Wong GL, Wong VW, Razavi H.
Aliment Pharmacol Ther. 2020 Apr;51(8):801-811. doi: 10.1111/apt.15673.

View Publication

Increased Release of Proinflammatory Proteins in Primary Human Adipocytes and Activation of the Inflammatory NFĸB, p38, and ERK Pathways upon Omentin Treatment.

Niersmann C, Röhrig K, Blüher M, Roden M, Herder C, Carstensen-Kirberg M.
Obes Facts. 2020 Apr 6:1-16. doi: 10.1159/000506405.

View Publication

Collagen biology and non-invasive biomarkers of liver fibrosis.

Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D.
Liver Int. 2020 Apr;40(4):736-750. doi: 10.1111/liv.14390.

View Publication

Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis.

Sehrawat TS, Arab JP, Liu M, Amrollahi P, Wan M, Fan J, Nakao Y, Pose E, Navarro-Corcuera A, Dasgupta D, Liao CY, He L, Mauer AS, Avitabile E, Ventura-Cots M, Bataller RA, Sanyal AJ, Chalasani NP, Heimbach JK, Watt KD, Gores GJ, Gines P, Kamath PS, Simonetto DA, Hu TY, Shah VH, Malhi H.
Hepatology. 2020 Apr 4. doi: 10.1002/hep.31256.

View Publication

Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease.

Rosso C, Caviglia GP, Younes R, Foglia B, Blanco MJG, Ribaldone DG, Bugianesi E.
Clin Lab. 2020 Apr 1;66(4). doi: 10.7754/Clin.Lab.2019.190922.

View Publication

Outcomes of liver transplantation by insurance types in the United States.

Stepanova M, Al Qahtani S, Mishra A, Younossi I, Venkatesan C, Younossi ZM.
Am J Manag Care. 2020 Apr 1;26(4):e121-e126. doi: 10.37765/ajmc.2020.42839.
PMID: 32270989

View Publication

Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy.

Sattari M, Bril F, Egerman R, Kalavalapalli S, Cusi K.
J Investig Med. 2020 Mar;68(3):743-747. doi: 10.1136/jim-2019-001186. Epub 2019 Dec 17.

View Publication

Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges.

Goldner D, Lavine JE.
Gastroenterology. 2020 Mar 20. pii: S0016-5085(20)30168-2. doi: 10.1053/j.gastro.2020.01.048.

View Publication

Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis.

Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H.
Hepatology. 2020 Mar 16. doi: 10.1002/hep.31236. [Epub ahead of print] Review.
PMID: 32176358

View Publication

Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks.

Han A, Byra M, Heba E, Andre MP, Erdman JW Jr, Loomba R, Sirlin CB, O'Brien WD Jr.
Radiology. 2020 Feb 25:191160. doi: 10.1148/radiol.2020191160.

View Publication

Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study.

VanWagner LB, Wilcox JE, Ning H, Lewis CE, Carr JJ, Rinella ME, Shah SJ, Lima JAC, Lloyd-Jones DM.
J Am Heart Assoc. 2020 Feb 18;9(4):e014279. doi: 10.1161/JAHA.119.014279.

View Publication

Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly.

Simon J, Nuñez-García M, Fernández-Tussy P, Barbier-Torres L, Fernández-Ramos D, Gómez-Santos B, Buqué X, Lopitz-Otsoa F, Goikoetxea-Usandizaga N, Serrano-Macia M, Rodriguez-Agudo R, Bizkarguenaga M, Zubiete-Franco I, Gutiérrez-de Juan V, Cabrera D, Alonso C, Iruzubieta P, Romero-Gomez M, van Liempd S, Castro A, Nogueiras R, Varela-Rey M, Falcón-Pérez JM, Villa E, Crespo J, Lu SC, Mato JM, Aspichueta P, Delgado TC, Martínez-Chantar ML.
Cell Metab. 2020 Feb 20. pii: S1550-4131(20)30056-5. doi: 10.1016/j.cmet.2020.01.013.

View Publication

Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease.

Musolino V, Gliozzi M, Scarano F, Bosco F, Scicchitano M, Nucera S, Carresi C, Ruga S, Zito MC, Maiuolo J, Macrì R, Amodio N, Juli G, Tassone P, Mollace R, Caffrey R, Marioneaux J, Walker R, Ehrlich J, Palma E, Muscoli C, Bedossa P, Salvemini D, Mollace V, Sanyal AJ.
Sci Rep. 2020 Feb 13;10(1):2565. doi: 10.1038/s41598-020-59485-3.

View Publication

Advances in non-invasive assessment of hepatic fibrosis.

Loomba R, Adams LA.
Gut. 2020 Feb 17. pii: gutjnl-2018-317593. doi: 10.1136/gutjnl-2018-317593.

View Publication

NAFLD 2020: The State of the Disease.

Cotter TG, Rinella M.
Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30223-7. doi: 10.1053/j.gastro.2020.01.052.

View Publication

An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.

Zhao P, Sun X, Chaggan C, Liao Z, In Wong K, He F, Singh S, Loomba R, Karin M, Witztum JL, Saltiel AR.
Science. 2020 Feb 7;367(6478):652-660. doi: 10.1126/science.aay0542.

View Publication

Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of Nonalcoholic Fatty Liver Disease.

Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM.
Hepatology. 2020 Feb 11. doi: 10.1002/hep.31173.

View Publication

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease.

Eslam M, Sanyal AJ, George J; an international consensus panel.
Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30171-2. doi: 10.1053/j.gastro.2019.11.312.

View Publication

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis.

Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN; Collaborators.
Gastroenterology. 2020 Feb 3. pii: S0016-5085(20)30137-2. doi: 10.1053/j.gastro.2020.01.043.

View Publication

Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.

Han A, Zhang YN, Boehringer AS, Montes V, Andre MP, Erdman JW Jr, Loomba R, Valasek MA, Sirlin CB, O'Brien WD Jr.
Radiology. 2020 Feb 4:191152. doi: 10.1148/radiol.2020191152.

View Publication

Investigating fibrosis and inflammation in an ex vivo NASH murine model.

Gore E, Bigaeva E, Oldenburger A, Jansen YJM, Schuppan D, Boersema M, Rippmann JF, Broermann A, Olinga P.
Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G336-G351. doi: 10.1152/ajpgi.00209.2019.

View Publication

Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?

Budd J, Cusi K.
Am J Med. 2020 Feb 1. pii: S0002-9343(20)30100-5. doi: 10.1016/j.amjmed.2020.01.007.

View Publication

The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management.

Berná G, Romero-Gomez M.
Liver Int. 2020 Feb;40 Suppl 1:102-108. doi: 10.1111/liv.14360. Review.

View Publication

Current management of non-alcoholic steatohepatitis.

Muthiah MD, Sanyal AJ.
Liver Int. 2020 Feb;40 Suppl 1:89-95. doi: 10.1111/liv.14355.

View Publication

New drugs for non-alcoholic steatohepatitis.

Cardoso AC, de Figueiredo-Mendes C, A Villela-Nogueira C, Sanyal AJ.

Liver Int. 2020 Feb;40 Suppl 1:96-101. doi: 10.1111/liv.14354.

View Publication

Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes.

Cusi K.
Diabetes Care. 2020 Feb;43(2):275-279. doi: 10.2337/dci19-0064.

View Publication

Role of Exercise in Mitigating Pediatric Nonalcoholic Fatty Liver Disease.

Vittorio JM, Lavine JE.
Diabetes Care. 2020 Feb;43(2):280-282. doi: 10.2337/dci19-0029.

View Publication

A diabetologist’s perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.

Cusi K.
Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.

View Publication

β-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosis.

Abe H, Schuppan D.
J Hepatol. 2020 May;72(5):813-815. doi: 10.1016/j.jhep.2020.01.016. Epub 2020 Feb 28.

View Publication

Fatty liver disease: putting the spotlight on a silent menace for young adults.

Bugianesi E.
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):236-238. doi: 10.1016/S2468-1253(19)30420-0. Epub 2020 Jan 15. No abstract available.
PMID: 31954686

View Publication

Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis.

Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, Kowdley K, Dasarathy S, Kleiner D, Behling C, Lavine J, Van Natta M, Middleton M, Tonascia J, Sirlin C; NASH Clinical Research Network.
Hepatology. 2020 Jan 21. doi: 10.1002/hep.31121.

View Publication

AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review.

Loomba R, Lim JK, Patton H, El-Serag HB.
Gastroenterology. 2020 Jan 29. pii: S0016-5085(20)30127-X. doi: 10.1053/j.gastro.2019.12.053.

View Publication

Collagen biology and non-invasive biomarkers of liver fibrosis.

Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D.
Liver Int. 2020 Jan 29. doi: 10.1111/liv.14390.

View Publication

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.

Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, Loomba R, Abdelmalek MF, Tacke F.
Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108.

View Publication

Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study.

Cleveland ER, Ning H, Vos MB, Lewis CE, Rinella ME, Carr JJ, Lloyd-Jones DM, VanWagner LB.
J Gen Intern Med. 2019 Dec;34(12):2772-2778. doi: 10.1007/s11606-019-05340-9.

View Publication

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.

Vos MB, Dimick-Santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Szitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, Miller V, Lavine JE; Liver Forum Pediatric Working Group.
Gastroenterology. 2019 Dec;157(6):1448-1456.e1. doi: 10.1053/j.gastro.2019.08.048.

View Publication

Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.

Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, Abate ML, Vilstrup H, Gastaldelli A, George J, Grønbæk H, Bugianesi E.
J Hepatol. 2019 Nov;71(5):1012-1021. doi: 10.1016/j.jhep.2019.06.031.

View Publication

The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease.

Paik JM, Deshpande R, Golabi P, Younossi I, Henry L, Younossi ZM.
Aliment Pharmacol Ther. 2019 Nov 29. doi: 10.1111/apt.15580.

View Publication

The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.

Balakrishnan M, Loomba R.
J Clin Gastroenterol. 2019 Nov 26. doi: 10.1097/MCG.0000000000001284.

View Publication

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

Poynard T, Peta V, Deckmyn O, Pais R, Ngo Y, Charlotte F, Ngo A, Munteanu M, Imbert-Bismut F, Monneret D, Housset C, Thabut D, Valla D, Boitard C, Castera L, Ratziu V; FLIP consortium, the FibroFrance Group, the EPIC-3 program and the QUID-NASH group.
Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001606.

View Publication

Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.

Majdi A, Aoudjehane L, Ratziu V, Islam T, Afonso MB, Conti F, Mestiri T, Lagouge M, Foufelle F, Ballenghien F, Ledent T, Moldes M, Cadoret A, Fouassier L, Delaunay JL, Aït-Slimane T, Courtois G, Fève B, Scatton O, Prip-Buus C, Rodrigues CMP, Housset C, Gautheron J.
J Hepatol. 2019 Nov 21. pii: S0168-8278(19)30678-6. doi: 10.1016/j.jhep.2019.11.008.

View Publication

Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease.

Ashfaq-Khan M, Aslam M, Qureshi MA, Senkowski MS, Yen-Weng S, Strand S, Kim YO, Pickert G, Schattenberg JM, Schuppan D.
Sci Rep. 2019 Nov 25;9(1):17463. doi: 10.1038/s41598-019-53323-x.

View Publication

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.

Pedrosa M, Seyedkazemi S, Francque S, Sanyal ARinella M, Charlton M, Loomba RRatziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM.
Contemp Clin Trials. 2019 Nov 13;88:105889. doi: 10.1016/j.cct.2019.105889.  

View Publication

Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes.

Younossi ZM, Tampi RP, Nader F, Younossi IM, Cable R, Srishord M, Racila A.
Liver Int. 2019 Nov 9. doi: 10.1111/liv.14292.   

View Publication

Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Golabi P, Rhea L, Henry L, Younossi ZM.
Hepatol Int. 2019 Nov;13(6):688-694. doi: 10.1007/s12072-019-09995-8.

View Publication

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC.
J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023.

View Publication

Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

Bril F, McPhaul MJ, Caulfield MP, Clark VC, Soldevilla-Pico C, Firpi-Morell RJ, Lai J, Shiffman D, Rowland CM, Cusi K.
Diabetes Care. 2019 Oct 11. pii: dc191071. doi: 10.2337/dc19-1071

View Publication

Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.

Bril F, Barb D, Lomonaco R, Lai J, Cusi K.
J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584-7. doi: 10.1016/j.jhep.2019.09.018

View Publication

Toward More Accurate Nomenclature for Fatty Liver Diseases

Eslam M, Sanyal AJ, George J.
Gastroenterology. 2019 Sep;157(3):590-593. doi: 10.1053/j.gastro.2019.05.064.

View Publication

Editorial: It is not a wide-open field for incretins – collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis

Ratziu V, Pais R.
Aliment Pharmacol Ther. 2019 Sep;50(5):611-612. doi: 10.1111/apt.15414.

View Publication

Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis

Borowa-Mazgaj B, de Conti A, Tryndyak V, Steward CR, Jimenez L, Melnyk S, Seneshaw M, Mirshahi F, Rusyn I, Beland FA, Sanyal AJ, Pogribny IP.
Toxicol Sci. 2019 Aug 1;170(2):273-282. doi: 10.1093/toxsci/kfz110.

View Publication

Non-alcoholic fatty liver disease in Asia: How is it different from the West?

Wong GL, Wong VW.
J Gastroenterol Hepatol. 2019 Aug;34(8):1267-1268. doi: 10.1111/jgh.14813.

View Publication

Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial

Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, Tio F, Suman A, Orsak BK, Hecht J, Cusi K.
Diabetes Care. 2019 Aug;42(8):1481-1488. doi: 10.2337/dc19-0167.

View Publication

Degradation of splicing factor SRSF3 contributes to progressive liver disease

Kumar D, Das M, Sauceda C, Ellies LG, Kuo K, Parwal P, Kaur M, Jih L, Bandyopadhyay GK, Burton D, Loomba R, Osborn O, Webster NJ.
J Clin Invest. 2019 Aug 8;130. pii: 127374. doi: 10.1172/JCI127374.

View Publication

FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice

Rohrbach TD, Asgharpour A, Maczis MA, Montefusco D, Cowart LA, Bedossa P, Sanyal AJ, Spiegel S.
J Lipid Res. 2019 Jul;60(7):1311-1322. doi: 10.1194/jlr.M093799.

View Publication

Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease

Nobili V, Mantovani A, Cianfarani S, Alisi A, Mosca A, Sartorelli MR, Maffeis C, Loomba R, Byrne CD, Targher G.
J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30395-2. doi: 10.1016/j.jhep.2019.06.023.

View Publication

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM.
Hepatology. 2019 Jul 4. doi: 10.1002/hep.30842.

View Publication

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A.
Aliment Pharmacol Ther. 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316

View Publication

Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications

Jayakumar S, Loomba R.
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314.

View Publication

A new bile acid treatment for non-alcoholic fatty liver disease

Chan WK, Wong VW.
Lancet Gastroenterol Hepatol. 2019 Jul 22. pii: S2468-1253(19)30183-9. doi: 10.1016/S2468-1253(19)30183-9.

View Publication

Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes

Bril F, Leeming DJ, Karsdal MA, Kalavalapalli S, Barb D, Lai J, Rabe M, Cusi K.
Diabetes Care. 2019 Jul;42(7):1348-1351. doi: 10.2337/dc18-2578.

View Publication

Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease

Khoo S, Wong VW, Goh GB, Fan J, Chan WK, Seto WK, Chow WC.
J Gastroenterol Hepatol. 2019 Jul 23. doi: 10.1111/jgh.14794.

View Publication

Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities

Fernando HJ, Cohen RA, Gullett JM, Friedman J, Ayzengart A, Porges E, Woods AJ, Gunstad J, Ochoa CM, Cusi K, Gonzalez-Louis R, Donahoo WT.
Obesity (Silver Spring). 2019 Jul;27(7):1099-1106. doi: 10.1002/oby.22508.

View Publication

REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis

Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z.
Contemp Clin Trials. 2019 Jun 29;84:105803. doi: 10.1016/j.cct.2019.06.017.

View Publication

Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention

Mouzaki M, Loomba R.
Therap Adv Gastroenterol. 2019 Jun 23;12:1756284819858470. doi: 10.1177/1756284819858470. eCollection 2019.  

View Publication

Development and Validation of Hepamet Fibrosis Scoring System A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Ming-Hua Z, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry.
Clin Gastroenterol Hepatol. 2019 Jun 11. pii: S1542-3565(19)30602-0. doi: 10.1016/j.cgh.2019.05.051.

View Publication

Past, present and future perspectives in nonalcoholic fatty liver disease.

Sanyal AJ.
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):377-386. doi: 10.1038/s41575-019-0144-8.

View Publication

Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.

Cusi K.
Hepatology. 2019 Jun;69(6):2318-2322. doi: 10.1002/hep.30670.

View Publication

Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.

Kalavalapalli S, Bril F, Guingab J, Vergara A, Garrett TJ, Sunny NE, Cusi K.
J Endocrinol. 2019 Jun 1;241(3):293-305. doi: 10.1530/JOE-19-0007.

View Publication

Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma.

Liang LY, Wong VW, Tse YK, Yip TC, Lui GC, Chan HL, Wong GL.
Aliment Pharmacol Ther. 2019 Jun;49(12):1509-1517. doi: 10.1111/apt.15269.

View Publication

Are Non-alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease More Than Just Semantics?

Eslam M, Sanyal AJ, George J.
Gastroenterology. 2019 May 31. pii: S0016-5085(19)40982-7. doi: 10.1053/j.gastro.2019.05.064

View Publication

Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis.

Farrell G, Schattenberg JM, Leclercq I, Yeh MM, Goldin R, Teoh N, Schuppan D.
Hepatology. 2019 May;69(5):2241-2257. doi: 10.1002/hep.30333.

View Publication

Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.

Bashir M, Wolfson T4, Gamst AC, Fowler KJ, Ohliger M, Shah SN, Alazraki A, Trout AT, Behling C, Allende DS, Loomba R, Sanyal A, Schwimmer J, Lavine JE, Shen W, Tonascia J, Van Natta ML, Mamidipalli A, Hooker J, Kowdley KV, Middleton MS, Sirlin CB; NASH Clinical Research Network (NASH CRN).
J Magn Reson Imaging. 2019 May;49(5):1456-1466. doi: 10.1002/jmri.26312.

View Publication

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum.

Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, Miller V; Liver Forum Case Definitions Working Group.
Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672.

View Publication

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group.
J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94. doi: 10.1097/QAI.0000000000001936.

View Publication

Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models.

Gallego-Durán R, Álvarez-Amor L, Gil-Gómez A, Rojas Á, Muñoz-Hernández R, Cádernas-García A, Maya-Miles D, Montero-Vallejo R, Gato S, Sánchez Torrijos Y, Ampuero J, Martín F, Romero-Gómez M.
Rev Esp Enferm Dig. 2019 Apr;111(4):301-307. doi: 10.17235/reed.2019.6083/2018.

View Publication

Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria.

Sánchez-Torrijos Y, Ampuero J, Pérez Palacios D, Gallego-Durán R, Romero-Gómez M.
Rev Esp Enferm Dig. 2019 Apr;111(4):270-274. doi: 10.17235/reed.2019.6088/2018.

View Publication

Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).

Fernández Rodríguez CM, Aller R, Gutiérrez García ML, Ampuero J, Gómez-Camarero J, Martín-Mateos RMª, Burgos-Santamaría D, Rosales JM, Aspichueta P, Buque X, Latorre M, Andrade RJ, Hernández-Guerra M, Romero-Gómez M.
Rev Esp Enferm Dig. 2019 Apr;111(4):264-269. doi: 10.17235/reed.2019.5965/2018.

View Publication

Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.

Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, Seekins D, Krishna G, Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N.
Aliment Pharmacol Ther. 2019 Mar;49(6):702-713. doi: 10.1111/apt.15153.

View Publication

Plasma Fibroblast Growth Factor 21 is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes.

Barb D, Bril F, Kalavalapalli S, Cusi K.
J Clin Endocrinol Metab. 2019 Mar 8. pii: jc.2018-02414. doi: 10.1210/jc.2018-02414.

View Publication

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis.

Poynard T, Peta V, Munteanu M, Charlotte F, Ngo Y, Ngo A, Perazzo H, Deckmyn O, Pais R, Mathurin P, Myers R, Loomba R, Ratziu V; FLIP consortium, the FibroFrance-CPAM group, the FibroFrance-Obese group, and the Selonsertib group.
Eur J Gastroenterol Hepatol. 2019 Mar;31(3):393-402. doi: 10.1097/MEG.0000000000001304.

View Publication

The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H.
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):145-159. doi: 10.1038/s41575-018-0082-x.

View Publication

Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis.

Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanoue T, Trauner M, Goodman Z, Harrison SA.
Clin Gastroenterol Hepatol. 2019 Feb 16. pii: S1542-3565(19)30187-9. doi: 10.1016/j.cgh.2019.02.024.

View Publication

Non-Invasive Assessment of Liver Disease in Patients with NAFLD.

Castera L, Friedrich-Rust M, Loomba R.
Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30051-4. doi: 10.1053/j.gastro.2018.12.036.

View Publication

Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.

Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G.
Transplantation. 2019 Jan;103(1):28-38. doi: 10.1097/TP.0000000000002483.

View Publication

Diagnostic Accuracy of Non-Invasive Fibrosis Models to Detect Change in Fibrosis Stage.

Siddiqui MS, Yamada G, Vuppalanchi R, Van Natta M, Loomba R, Guy C, Brandman D, Tonanscia J, Chalasani N, Neuschander-Tetri B, Sanyal AJ; NASH Clinical Research Network.
Clin Gastroenterol Hepatol. 2019 Jan 4. pii: S1542-3565(19)30004-7. doi: 10.1016/j.cgh.2018.12.031.

View Publication

Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis.

Banini B, Cazanave SC, Yates KP, Asgharpour A, Vincent R, Mirshahi F, Le P, Contos MJ, Tonascia J, Chalasani NP, Kowdley KV, McCullough AJ, Behling CA, Schwimmer JB, Lavine JE, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).
J Clin Gastroenterol. 2018 Dec 21. doi: 10.1097/MCG.0000000000001142.

View Publication